

1 5 **Title:** Loss of Pigment Epithelium Derived Factor Sensitizes C57BL/6J Mice to Light-Induced  
2 Retinal Damage

3

4 **Authors:** Debresha A. Shelton<sup>1</sup>, Jack T. Papania<sup>1</sup>, Tatiana E. Getz<sup>1</sup>, Jana T. Sellers<sup>1</sup>, Preston E.  
5 Giradot<sup>1</sup>, Micah A. Chrenek<sup>1</sup>, Hans E. Grossniklaus<sup>1</sup>, Jeffrey H. Boatright<sup>1,2</sup>, John M. Nickerson<sup>1</sup>

6

7 Affiliations:

8 <sup>1</sup>Department of Ophthalmology, Emory University, Atlanta, Georgia, United States

9 <sup>2</sup>Atlanta Veterans Administration Center for Visual and Neurocognitive Rehabilitation, Decatur, Georgia,

10 United States

11

12 Correspondence to: Please address all correspondence to Dr. John M. Nickerson; Department of  
13 Ophthalmology, Emory University, B5602, 1365B Clifton Road, NE, Atlanta, GA, 30322; Phone 404-  
14 778-4411; email: [litjn@emory.edu](mailto:litjn@emory.edu)

15

16 Funding: Supported by National Institutes of Health (NIH) grants R01EY028450, R01EY021592,  
17 P30EY006360, R01EY028859, T32EY07092, and T32GM008490, the Abraham and Phyllis Katz  
18 Foundation, VA RR&D I01RX002806 and I21RX001924, VA RR&D C9246C (Atlanta Veterans  
19 Administration Center for Excellence in Vision and Neurocognitive Rehabilitation), and a challenge grant  
20 to the Department of Ophthalmology at Emory University from Research to Prevent Blindness, Inc.

21

## 22 5.1 ABSTRACT

### 23 **Purpose:**

24 Pigment epithelium-derived factor (PEDF) is a neurotrophic glycoprotein secreted by the  
25 retinal pigment epithelium (RPE) that supports retinal photoreceptor health. Deficits in  
26 PEDF are associated with increased inflammation and retinal degeneration in aging and  
27 diabetic retinopathy. We hypothesized that light-induced stress in C57BL/6J mice deficient  
28 in PEDF would lead to increased retinal neuronal and RPE defects, impaired expression of  
29 neurotrophic factor Insulin-like growth factor 1 (IGF-1), and overactivation of Galectin-3-  
30 mediated inflammatory signaling.

### 31 **Methods:**

32 C57BL/6J mice expressing the RPE65 M450/M450 allele were crossed to PEDF<sup>KO/KO</sup> and  
33 wildtype (PEDF<sup>+/+</sup>) littermates. Mice were exposed to 50,000 lux light for 5 hours to  
34 initiate acute damage. Changes in visual function outcomes were tracked via  
35 electroretinogram (ERG), confocal scanning laser ophthalmoscopy (cSLO), and spectral  
36 domain optical coherence tomography (SD-OCT) on days 3, 5, and 7 post-light exposure.  
37 Gene and protein expression of Galectin-3 were measured by digital drop PCR (ddPCR) and  
38 western blot. To further investigate the role of galectin-3 on visual outcomes and PEDF  
39 expression after damage, we also used a small-molecule inhibitor to reduce its activity.

### 40 **Results:**

41 Following light damage, PEDF<sup>KO/KO</sup> mice showed more severe retinal thinning, impaired  
42 visual function (reduced a-, b-, and c-wave amplitudes), and increased Galectin-3 expressing  
43 immune cell infiltration compared to PEDF<sup>+/+</sup>. PEDF<sup>KO/KO</sup> mice had suppressed damage-

44 associated increases in IGF-1 expression. Additionally, baseline Galectin-3 mRNA and  
45 protein expression were reduced in PEDF<sup>KO/KO</sup> mice compared to PEDF<sup>+/+</sup>. However, after  
46 light damage, Galectin-3 expression decreases in PEDF<sup>+/+</sup> mice but increases in PEDF  
47 KO/KO mice without reaching PEDF<sup>+/+</sup> levels. Galectin-3 inhibition worsens retinal  
48 degeneration, reduces PEDF expression in PEDF<sup>+/+</sup> mice, and mimics the effects seen in  
49 PEDF knockouts.

50 **Conclusions:**

51 Loss of PEDF alone does not elicit functional defects in C57BL/6J mice. However, under  
52 light stress, PEDF deficiency significantly increases severe retinal degeneration, visual  
53 deficits, Galectin-3 expression, and suppression of IGF-1 than PEDF<sup>+/+</sup>. PEDF deficiency  
54 reduced baseline expression of Galectin-3, and pharmacological inhibition of Galectin-3  
55 worsens outcomes and suppresses PEDF expression in PEDF<sup>+/+</sup>, suggesting a novel co-  
56 regulatory relationship between the two proteins in mitigating light-induced retinal damage.

57

## 58 5.2 INTRODUCTION

59 Pigment epithelium-derived factor (PEDF), a secreted 50-kDa glycoprotein with neurotrophic  
60 effects, is critical in the development and homeostasis of the vertebrate eye<sup>1-4</sup>. While other ocular  
61 tissues express PEDF, the retinal pigment epithelium (RPE) is the primary producer of PEDF and is  
62 crucial for retinal health and visual signaling.<sup>5-9</sup> RPE ablation studies have shown that loss of the  
63 RPE leads to disorganization of multiple retinal layers during development; however,  
64 supplementation with PEDF is sufficient to rescue this phenotype in *X. leavis* in ex vivo tissue  
65 culture models<sup>1</sup>. Similarly, loss of the RPE and PEDF expression in the eye is associated with  
66 aging<sup>2,10,11</sup> and ocular pathology<sup>12,13</sup>, including diabetic retinopathy<sup>14,15</sup> and vascular glaucoma<sup>15</sup>.  
67 PEDF has putative anti-inflammatory roles in eye<sup>16,17</sup> and was first described as an anti-tumor factor  
68 by Tombran-Tink and colleagues in 1990 because of its ability to differentiate retinoblastoma  
69 cells<sup>18,19</sup>. Since then, multiple studies have identified PEDF as a significant support in cellular  
70 differentiation, retinal development, inflammation, vascularization, and neuroprotection of  
71 photoreceptors and neurons<sup>7,20-27</sup>. In this study, we asked if PEDF has a protective role in the retina  
72 and RPE following LIRD in a C57BL/6J mouse strain that confers resistance to light damage.

73  
74 In 2006, An et al. studied the secreted proteome of RPE cell cultures isolated from patients with  
75 AMD and compared them to control eyes<sup>28,29</sup>. Interestingly, they found a 3-fold increase in the  
76 secretion of four proteins in eye patients with age-related macular degeneration (AMD) compared to  
77 controls; among them were galectin-3 (Lgals3) and pigment epithelium-derived factor (PEDF),  
78 suggesting that both may be involved in the pathology of the phenotype. Galectin-3, a member of the  
79  $\beta$ -galactosidase binding protein family, is endogenously expressed in the cytosol. Galectin-3 is  
80 secreted via a non-classical pathway to the cell surface of the RPE, where it participates in a cell  
81 lattice formation and cell-cell interaction observed during EMT of myofibroblastic RPE cells<sup>30,31</sup>  
82 Galectin-3 has also been implicated in fine-tuning inflammatory responses of immune cells during  
83 neurodegeneration via its increased affinity for  $\beta$ -1, 6-N- glycosylation on the cell surface of RPE

84 cells undergoing EMT and the increased secretion from RPE and immune cells after damage<sup>30-35</sup>.

85 However, the role that PEDF expression may play in the modulation of galectin-3 after damage in  
86 the eye is not fully understood.

87

88 This study identified a novel potential molecular target and signaling pathway that connects the RPE  
89 and inflammation via a PEDF-Galectin-3 mediated signaling paradigm. The interplay between PEDF  
90 and Galectin-3 may reveal an additional level of regulation of ocular immune privilege facilitated by  
91 the RPE over immune cell behavior. Using *in vivo* imaging techniques, electroretinograms, protein  
92 and gene expression analysis, and immunofluorescence, we examine how the loss of PEDF  
93 expression after light damage increases galectin-3 expression, recruitment of subretinal immune  
94 cells, and progressive loss of visual structures and function over time. These findings support the  
95 importance of PEDF in protecting eye tissues against LIRD.

96

### 97 **5.3 METHODS**

98

#### 99 **5.3.4 Animal husbandry**

100 The Emory University Institutional Animal Care and Use Committee approved mouse handling,  
101 care, housing, and experimental design. The experiments were compiled with the Association for  
102 Research in Vision and Ophthalmology (ARVO) and Accreditation of Laboratory Animal Care  
103 (AAALAC) guidelines and doctrine. Mice were housed and maintained on a 12-hour light/dark cycle  
104 at 22 °C, with standardized rodent chow (Lab Diet 5001; PMI Nutrition Inc., LLC, Brentwood, MO,  
105 USA). Mice had access to water *ad libitum*. The Emory University Division of Animal Resources  
106 supervised mouse care and housing. A roughly equal representation of male and female mice was  
107 used in all experiments. Animals were euthanized using standardized asphyxiation via CO<sub>2</sub> gas for 5  
108 min, followed by confirmatory cervical dislocation.

109

### 110 **5.3.5 Breeding Scheme**

111 PEDF knockout/null (PEDF<sup>KO/KO</sup> or PEDF-null) mice, which were gifted from Dr. Hans  
112 Grossniklaus and Dr. Sue Crawford at Northwestern University Feinberg School of Medicine (JAX  
113 Laboratory Stock No. 030065). This mouse strain has had exons 3-6 of the PEDF gene replaced by  
114 an IRES-lacZ cassette systemically. We bred PEDF(ko/+) x PEDF(ko/+) on the RPE65<sup>M450/M450</sup> on  
115 C57BL/6J. The breeding scheme resulted in litters that were approximately 25% PEDF<sup>KO/KO</sup>  
116 (experimental) and 25% PEDF<sup>+/+</sup> (wildtype controls). These mice were used for all protein and gene  
117 expression analysis. To assess immune cell dynamics we used CX3CR-1<sup>GFP</sup> knock-in mice on the  
118 C57BL/6J background were acquired from Jackson Laboratory (Stock NO. 005582). We maintained  
119 a line that was homozygous for PEDF-ko and another line that was homozygous for PEDF-wt. Both  
120 sets of mice were then bred to produce heterozygous CX3CR1(gfp/+) on the RPE65<sup>M450/M450</sup>  
121 background. The resultant animals were either PEDF<sup>KO/KO</sup>; CX3CR-1<sup>GFP/+</sup>; RPE65<sup>M450/M450</sup> or  
122 PEDF<sup>+/+</sup>; CX3CR1<sup>GFP/GFP</sup>; RPE65<sup>M450/M450</sup>. All PEDF<sup>KO/KO</sup> experiments were conducted in animals  
123 that were more than P60 but less than P380. Genotyping was performed using a polymerase chain  
124 reaction to confirm the deletion of the PEDF gene product. The genotyping results were hidden from  
125 experimental biologists until after in vivo experiments, and samples were collected to limit  
126 ascertainment biases.

127

### 128 **5.3.6 Light-induced retinal damage (LIRD) conditions and LIRD box information**

129 Mice were dark-adapted overnight before light damage initiation. Phototoxic light damage was  
130 induced using Fancier 500-A LED light lamp panels (Fancier Studio, Haywood, CA), which was  
131 modified to fit on transparent polycarbonate model 750 cages. The protocol is a modification of  
132 previously described phototoxic damage models<sup>36,37</sup>. The light intensity was calibrated using a VWR  
133 ® Light Meter with outputs (catalog No. 62344-944, Radnor, PA) to 50,000 lux. The mice were  
134 treated with topical 1% Atropine eye drops for two rounds of 10 seconds per eye. Mice were exposed

135 to high-intensity light damage for 5 hours during the dark phase of the animals (7PM-12 AM or  
136 ZT12- ZT17). After light damage, animals were returned to their home cages for recovery.

### 137 **5.3.7** Immunofluorescence staining and Histology.

#### 138 **5.3.7.1** RPE Flat mounts:

139 Immunofluorescence was used to detect galectin-3 positive cells and RPE cells to assess the extent  
140 of immune cell recruitment and damage. Samples were dissected using the technique reported by  
141 Zhang et al.<sup>38-40</sup>. In brief, after enucleation, the eye is placed into a 4% Paraformaldehyde/PBS  
142 mixture to incubate for 30 minutes. The lens was removed, and four flaps were made to flatten the  
143 RPE sheet to a conventional slide with an adhered silicon gasket (Grace Bio-Labs, Bend, OR). The  
144 RPE flat mounts were blocked in Hank's Balanced salt solution (#SH30588.01; Hyclone, Logan,  
145 UT) containing 0.3 % (V/V) Triton X-100 and 1% (W/V) bovine serum albumin for 1 hour at 22 °C  
146 or overnight at 4°C in a humidity chamber. The samples were then stained with Galectin-3 (1:250),  
147 Vimentin (1:250), IGF-1(1:250), and ZO-1(1:200) overnight at 4°C. The next day, the flat mounts  
148 were washed with HBSS/Triton X-100 solution and incubated in secondary antibody in HBSS/  
149 Triton 100 X/BSA solution for 1 hour at 22°C. After secondary incubation, samples were washed  
150 with HBSS/Triton 100 X solution before mounting with fluoromount G.

151

#### 152 **5.3.7.2** Retinal Sections

153 Eyes were fixed in fixation solution (97% methanol, VWR, Cat. #BDH20291GLP; 3% acetic acid,  
154 Cat. #Fisher BP2401-500) at -80 °C for 4 days, embedded in paraffin, and sectioned through the  
155 sagittal plane on a microtome at thickness of 5 µm as previously described by Sun et al<sup>41</sup>. Nuclei in  
156 the outer nuclear layer (ONL) were counted manually by an individual masked to sample identity.  
157 Only nuclei within a 100-micron region were counted using Adobe Photoshop (Version 27.4.0) at  
158 regularly spaced intervals of 500 microns apart from the optic nerve in both the inferior and superior  
159 directions. Deparaffinized retinal sections were also stained for immunofluorescence in a humidity  
160 chamber as described by Zhang et al<sup>38</sup>. Slides were mounted using Vectashield Vibrance (Vector

161 Labs H-1700-2; Newark, CA) was used to mount the coverslip, and the sections were imaged using  
162 an A1R confocal on a Nikon Ti2 microscope. All primary and secondary antibodies used for this  
163 study are listed in [Table 1](#).

164

### 165 **5.3.8** Rhodopsin staining assay

166 Animals were euthanized, and eye samples were collected within 1 hour of light onset (between ZT0  
167 and ZT1) to capture maximal phagosome production. Murine eyes were enucleated and placed in  
168 glass tubes of “freeze-sub” solution of 97% methanol (Fisher Scientific A433p-4) and 3% acetic acid  
169 that was chilled with dry ice, following the method of Sun and coworkers<sup>42</sup>. Tubes were placed at -  
170 80°C for at least four days to dehydrate the tissue. The sections were then treated as described in  
171 section 2.4.2. The primary antibodies (mouse anti-rhodopsin, Abcam, catalog #ab3267, [1:250] and  
172 Rabbit anti-BEST1, Abcam, catalog # ab14927 [1:250]) are then added to the blocking solution and  
173 put on the slides overnight at room temperature in a humidified chamber. The next day, the  
174 secondary antibody is added to the blocking solution. Slides were washed and nuclei stained before  
175 mounting in fluoromount G (catalog #0100-01; SouthernBiotech, Birmingham, AL, USA). The shed  
176 rod outer segments (rhodopsin-positive vesicles) within RPE were quantified as phagosomes. Counts  
177 were performed by three independent, masked observers using Photoshop (Adobe Photoshop,  
178 Version 27.4.0), and each count was averaged for final counts per sample.

179

180

### 181 **5.3.9** Electroretinogram

182 Mice were dark-adapted overnight for ERG testing, conducted under dim red light conditions as  
183 previously described<sup>43</sup>. Anesthesia was administered intraperitoneally with a 100 mg/kg ketamine  
184 and 10 mg/kg xylazine solution ketamine; KetaVed from Boehringer Ingelheim Vetmedica, Inc., Fort  
185 Dodge, IA (CAS # 1867-66-9); xylazine from PivetalVet, Greeley, CO, USA. Proparacaine (1%;  
186 Akorn Inc.) and tropicamide (1%; Akorn Inc.) eyedrops were used for topical anesthesia and pupil



187 dilation. Mice were kept on a 39 °C heating pad during the procedure. ERGs were recorded using the  
188 Diagnosys Celeris system (Diagnosys, LLC, Lowell, MA, USA), with corneal electrodes on each  
189 eye and the contralateral eye as the reference. Full-field ERGs were recorded for scotopic conditions  
190 at stimulus intensities of 0.001, 0.005, 0.01, 0.1, and 1 cd s/m<sup>2</sup> with a 4 ms flash duration, collecting  
191 signals for 0.3 sec to assess a- and b-wave function. For c-wave analysis, a 10 cd s/m<sup>2</sup> flash was  
192 used, with a 5-sec signal collection. After light adaptation for 10 minutes, photopic ERGs were  
193 captured at 3 and 10 cd s/m<sup>2</sup>. Post-recording, mice were placed in their home cages on heating pads  
194 to recover from anesthesia unless further prepared for SD-OCT and cSLO examinations.

### 195 **5.3.10 In Vivo Ocular Imaging**

196

#### 197 **5.3.10.1 Spectral Domain Optical Coherence Tomography (SD-OCT):**

198 Mice were anesthetized during the previous ERG examination, and a ketamine booster was administered  
199 to extend the examination period. The procedure for in vivo ocular posterior segment morphology  
200 analysis has been previously described<sup>38</sup>. In brief, spectral domain optical coherence tomography (SD-  
201 OCT) using the MICRON<sup>®</sup> IV Spectral Domain Optical Coherence Tomography (SD-OCT) system with  
202 a fundus camera (Phoenix Research Labs, Pleasanton, CA, USA) was used sequentially to examine the  
203 retinal anatomy. Micron IV system, circular scans ~100 µm from the optic nerve head were collected (50  
204 scans averaged together) to generate image-guided OCT images of retinal layers and fundus. Retinal  
205 layers were annotated according to previously published nomenclature<sup>44</sup>Total retinal thickness and  
206 photoreceptor (outer nuclear layer thickness) were analyzed using Photoshop (Adobe Photoshop 2024  
207 version 25.5) as previously described<sup>38</sup>.

208

#### 209 **5.3.10.2 Confocal Scanning Laser Ophthalmoscope (cSLO)**

210 Immediately afterward, a rigid, specialized contact lens adapted for mouse imaging (Heidelberg  
211 Engineering) was placed on the eye (back optic zone radius, 1.7 mm; diameter, 3.2 mm; power, Plano),  
212 and blue autofluorescence (BAF) imaging at the layer of the photoreceptor-RPE was obtained using

213 Heidelberg Spectralis and SD-OCT instrument with a 25 D lens (HRA)CT2-MC; Heidelberg Engineering,  
214 Heidelberg, Germany). Afterward, mice were injected with a reversal agent (0.5 mg/mL  
215 atipamezole(Antisedan); Zoetis, Parsippany, NJ) injection volume 5  $\mu$ L per gram mouse weight; and  
216 placed individually in cages on top of heated water pads to recover.

217

218

### 219 **5.3.11** Western Blot Protocol

220 As described in Ferdous et al. 2019 and Ferdous et al. 2023, immunoblot experiments were  
221 conducted. In brief, two dissected eye cups (containing both the retina and RPE/ Sclera) were  
222 collected from each animal. Protein was extracted via mechanical rending of tissue by a QIAGEN  
223 TissueLyser in a solution of radioimmunoprecipitation (RIPA) buffer containing protease inhibitors  
224 (completed mini protein inhibitor catalog #118361530001) and phosphatase inhibitors (PhosSTOP  
225 EASypack #04906845001). Protein concentration was determined using Pierce bicinchonic Acid  
226 (BCA) Assay, and absorbance was measured at 562 nm using a Synergy H1 Hybrid Plate Reader  
227 (Biotek). After ascertaining protein concentration, the samples were diluted to 0.8 mg/mL and heated  
228 to 95 °C for 10 minutes to denature proteins before electrophoresis. Samples were run on a pre-cast  
229 Criterion gel (Biorad TGX Stain free Gel 4%-20%, Catalog # 567-8094) along with 10 $\mu$ L of a  
230 molecular weight ladder (Bio-Rad Catalog # 1610376) and run at 120V for 90 mins.

231

### 232 **5.3.12** TUNEL Staining protocol

233 The manufacturer instructions for the Promega DeadEnd TUNEL Fluorometric kit (Promega G3250)  
234 were followed. In brief, tissue sections were deparaffinized in 5 steps of xylene for 2 min each. The  
235 tissue sections were then rehydrated in a graded ethanol series (100, 90, 80, 70, 60, and 50%) for 2  
236 min each. The slides were then washed for 5 min in PBS (Corning 46-013-CM) and mounted in the  
237 Sequenza system. Sections were incubated for 15 min in Z-fix (Anatech, Fisher Scientific  
238 NC935141), washed twice in PBS for 5 min each, incubated in Proteinase K solution for 8 min,

239 washed with PBS for 5 min, fixed with Z-fix for 5 min, washed with PBS for 5 min, incubated with  
240 rTDT enzyme and nucleotide mix in equilibration buffer for two hours, washed with 2× SSC for 5  
241 min, counterstained with 2.5 m Hoechst 33342 in TBS for 10 min, and rinsed with TBS for 5 min.  
242 Coverslips were then mounted using VectaShield Vibrance and imaged using an A1R confocal on a  
243 Nikon Ti2 microscope.

244

### 245 **5.3.13 Galectin-3 inhibitor experiments**

246 At baseline, animals were assessed by electroretinogram, spectral domain coherence tomography  
247 (SD-OCT), and confocal scanning laser ophthalmoscope (CSLO) to evaluate any inherent structural  
248 or functional features or defects. Animals were injected with 15mg/kg of TD139 (33DFTG, catalog #  
249 AOB37408, AOBIOUS, Inc. Scranton, Pennsylvania) intraperitoneally daily beginning one day  
250 before light damage administration until day five post damage. Animals were then assessed using the  
251 same in vivo measures for retina architecture and structure changes.

252

### 253 **5.3.14 Gene expression analysis (digital drop PCR)**

254 Eyes were collected between 10 AM and 2 PM to standardize gene expression. The cornea and iris  
255 were removed via an incision, followed by the lens, and the neuroretina was separated from the  
256 RPE/choroid eye cup. Retinas were flash-frozen in RNase-free tubes and pre-chilled on dry ice.  
257 RPE/choroid eye cups were incubated in RNeasy Protect<sup>®</sup> Cell Reagent (Qiagen, Cat # 76106,  
258 Germantown, Maryland). for 10 minutes, with occasional agitation to release RPE cells. Cells were  
259 pelleted by centrifugation (>12,000 x g for 5 minutes), the supernatant was discarded, and the cells  
260 were stored at -80°C. RNA extraction was performed using the Qiagen RNeasy Mini Kit (Cat  
261 #74106). Samples were homogenized in RLT buffer with a stainless-steel bead, followed by ethanol  
262 addition and vortexing. The mixture was processed through an RNeasy column, washed with RW1  
263 and RPE buffers, and eluted with nuclease-free water. The final RNA samples were stored at -80°C.  
264 cDNA synthesis was conducted using the Qiagen Quantitect RT kit.

265 Digital drop PCR (ddPCR) Reactions

266 Reaction mixes containing reverse transcriptase, primers, RT buffer, and QX200™ ddPCR  
267 EvaGreen Supermix (Bio-Rad: 186–4034) were added to 2µL of cDNA template for a total volume  
268 of 20 µL /well on the plate Twin-Tec plate (CAS # 951020320; Eppendorf, Enfield, CT). Fill empty  
269 well with RT Buffer and seal plate with tape film and spin down and mix. Plates were preheated at  
270 95 C for 2 min/cycle. After using the droplet generator to generate droplets on the ddPCR plate, seal  
271 the droplet plate with foil film using the Biorad program. Then place the sealed Twin-Tec plate into  
272 ddPCR apparatus (QX200 Droplet Digital PCR (ddPCR™) System – Bio-Rad) and run the program  
273 as detailed in manufacturer’s manual.

274

275

276

277 **5.3.15** Imaris analysis

278 The intensity, size, and distribution of Galectin-3 positive immune cells were analyzed using Imaris  
279 software 10.1.0 by Bitplane. Maximum intensity projection images of each RPE flat mount were  
280 processed using IMARIS 10.1.0 (Bitplane, Inc.), in which individual cells were identified,  
281 segmented, and quantified morphologically. Before converting and uploading images to Imaris, the  
282 corneal flaps and optic nerve heads were removed via the crop tool in Photoshop. Subretinal immune  
283 cell counts were conducted using the spots function in Imaris (artifacts and cell particulates were  
284 manually rejected) so that only cells with intact soma were quantified. Cell counts were normalized  
285 against double-blind manual cell counts of the same samples.

286

287 **5.3.16** Statistical analysis

288 Statistical analysis was conducted using Prism 9.1.0 (on Mac OS X 14 Sonoma) (GraphPad  
289 Software, Inc., La Jolla, CA, USA). Data are presented as mean +/- standard deviation (SD), with  
290 statistical testing for individual datasets described in the Figure legends. A p-value <0.05 was  
291 considered statistically significant. Demographic distributions and sample sizes are summarized in  
292 Table 1. All statistical tests used are detailed in the Figure Legends.

293

294 Table 1: antibody and reagent information

<b>Antibody</b>	<b>Antibody Type</b>	<b>Species</b>	<b>Company and Catalog information</b>	<b>Concentration</b>
<b>Galectin-3</b>	Primary	Goat	R&D Systems ( AF1197)	1:250
<b>ZO-1</b>	Primary	Rat	Sigma	1:250
<b>Vimentin(D21H3)</b>	Primary	Rabbit	Cell Signaling (mAB5741S)	1:200
<b>IGF-1</b>	Primary (conjugated AF546)	Mouse	Santa Cruz (sc-518040)	1:100
<b>IBA-1</b>	Primary	Rabbit	Abcam (ab178847)	(1:1000)
<b>Pentahydrate(bis-Benzamide)Hoechst 33258</b>	DNA nuclear Stain	N/A	Thermo-Fisher Catalog #: H3569	[1:250]
<b>TUNEL</b>	N/A	N/A	Promega DeadEnd TUNEL Fluorometric Kit- G3250	
<b>Mouse anti-Rhodopsin</b>	Primary	Mouse	Abcam, ab3267	[1:250]
<b>Rabbit anti-Best1</b>	Primary	Rabbit	Abcam, ab14927	[1:250]
<b>Donkey anti-Rat (AF488)</b>	Secondary	Rat	Life Technologies, Catalog # A21208	[1:1000]
<b>Donkey anti-rabbit (AF568)</b>	Secondary	Rabbit	Life Technologies, Catalog # A10042	[1:1000]
<b>Donkey Anti-Mouse(AF488)</b>	Secondary	Mouse	Life Technologies Catalog #A21202	[1:1000]
<b>Donkey Anti-Goat(AF647)</b>	Secondary	Goat	Abcam Catalog # A32849	[1:1000]

295

296

297

298 Table 2: Digital Drop PCR Primer sequences

<b>Gene</b>	<b>Protein</b>	<b>Primer Sequence</b>	<b>Size</b>	<b>Species</b>
<i>Hrpt</i>	HRPT- HEX(IDT)	Mm.PT.39a22214828		Mouse
<i>Il6</i>	IL6	dMmuCPE5095532	<b>70</b>	Mouse
<i>Il1b</i>	IL1B	Mm.PT.58.41616450	119	Mouse
<i>Lgals3</i>	Galectin- 3	Mm.PT.58.8335884	130	Mouse
<i>Nlrp3</i>	NLRP3	Mm.PT.58.13974318	90	Mouse
<i>Snai1</i>	SNAI1	Mm.PT.58.43057042	122	Mouse

299

300

## 301 5.4 RESULTS

### 302 5.4.1 Figure 1: Loss of PEDF is a Phenotype Modifier for Sensitivity to Phototoxic Damage in 303 C57BL/6J

304 Expression of PEDF protects neurons and photoreceptors<sup>26,45,46</sup>. Conversely, loss of PEDF is linked  
305 to neurodegenerative disease phenotypes, including an autosomal dominant retinitis pigmentosa  
306 locus in human studies<sup>24,47</sup>. To determine if loss of PEDF sensitizes C57BL/6J mice to phototoxic  
307 damage, we crossed PEDF-null mice to mice with a hypomorphic mutation in the RPE65 gene,  
308 resulting in reduced sensitivity to light damage. We exposed these animals to 50,000 lux of light  
309 for 5 hours. We found that PEDF-null animals had more mottling in the fundus after LIRD than  
310 wildtype controls and experienced more retinal degeneration and thinning (see Figure. 1E-F). We  
311 quantified these changes amongst PEDF<sup>+/+</sup>, PEDF<sup>+/-</sup>, and PEDF<sup>KO/KO</sup>. We found that PEDF<sup>+/-</sup>  
312 behaved very similarly to PEDF<sup>+/+</sup> animals and showed minimal perturbances to ocular structure  
313 after LIRD (Fig. 1G-H). However, PEDF<sup>KO/KO</sup> showed significant losses of photoreceptor thickness  
314 and total retinal thickness compared to PEDF<sup>+/+</sup> and PEDF<sup>+/-</sup> animals (Figure 1G-H). Analysis: One-  
315 way ANOVA with Brown-Forsythe test and Barlett's correction. Retinal thickness: PEDF<sup>+/+</sup> vs.  
316 PEDF<sup>+/-</sup> p-value= not significant(ns); PEDF<sup>+/+</sup> vs. PEDF<sup>KO/KO</sup> \*\*p-value<0.01; PEDF<sup>+/-</sup> vs. PEDF<sup>KO/KO</sup>  
317 \*\*p-value0.01. Photoreceptor thickness: PEDF<sup>+/+</sup> vs. PEDF<sup>+/-</sup> = ns; PEDF<sup>+/+</sup> vs. PEDF<sup>KO/KO</sup>  
318 \*\*\*\*p-value<0.0001; PEDF<sup>+/-</sup> vs. PEDF<sup>KO/KO</sup> \*\*\*\*p-value<0.000. PEDF<sup>+/+</sup> n=5, PEDF<sup>+/-</sup> n=4,  
319 PEDF<sup>KO/KO</sup> n=4). This data suggests that PEDF is protective against increased phototoxic damage.

320

### 321 5.4.2 Figure 2: Loss of PEDF increases damage-associated autofluorescent dots at the level of the 322 RPE

323 We used cSLO to capture dynamic changes at the level of the photoreceptor-RPE interface. At  
324 baseline, there were no differences or abnormalities between PEDF<sup>+/+</sup> (2A-B) or PEDF<sup>KO/KO</sup> (2F-  
325 G) in the vasculature or at the level of the RPE interface. However, when assessing the same



326 animals on Day 7, the number of damage-associated punctate at the RPE-photoreceptor layer was  
327 significantly increased in the PEDF<sup>KO/KO</sup>(2H-J) animals compared to the PEDF<sup>+/+</sup> (2C-E). This  
328 data suggests that PEDF-null animals have improved response to damage via the appearance of  
329 damage-associated foci at the RPE-photoreceptor interface.

330

331 **5.4.3 Figure 3A: There is regionality to the damage phenotype in PEDF knockouts compared to**  
332 **the wild type.**

333 We used H&E to quantify the number of nuclei remaining in the outer nuclear layer (ONL) after LIRD  
334 damage to assess the degree of the damage and morphological changes. PEDF<sup>+/+</sup> animals still had  
335 relatively normal morphology with intact RPE layer and photoreceptor inner and outer segments before  
336 and after LIRD (Figure 3A-B). However, the PEDF<sup>KO/KO</sup> animal displayed a significant loss of total  
337 retinal thickness, a drastically diminished ONL, an almost complete loss of photoreceptor inner and outer  
338 segments, and compromised RPE integrity (shown via white arrows: differences in RPE thickness; Fig.  
339 3C-D). There were regional characteristics to this damage phenotype in the PEDF<sup>KO/KO</sup> animals, with  
340 retinal structures on the superior portion of the eye being more severely diminished compared to the  
341 inferior region of the eye (Fig.3E). A similar phenotype was also shown in day five after damage [data not  
342 shown]. (Analysis: One-way ANOVA with Brown-Forsythe test and Barlett's correction; <sup>##</sup> p-value<0.01  
343 and <sup>###</sup>p-value< 0.001; PEDF<sup>+/+</sup> n=4, PEDF<sup>KO/KO</sup> n=4). This phenomenon is characteristic of light  
344 damage models, as described by Rapp and Williams<sup>48,49</sup> and our data confirms that.

345 Previous light studies in rats have suggested that peak DNA damage occurs within the first 8-16  
346 hours after damage<sup>50</sup>. To assess if PEDF<sup>KO/KO</sup> animals were still undergoing significant levels of active  
347 apoptosis at day 7, we stained for DNA fragmentation using TUNEL and immune cells using CX3CR1-  
348 GFP. PEDF<sup>KO/KO</sup> animals had significantly more apoptotic cells at day 7, resulting in a more depleted  
349 outer nuclear layer than wild-type controls. Additionally, there are more immune cells in the PEDF<sup>KO/KO</sup>  
350 subretinal space compared to the wild-type animals at the same time point (Fig. 3L-N; quantified in Fig.  
351 3O: Analysis: One-way ANOVA with Tukey's multiple comparison tests: untreated vs. PEDF<sup>+/+</sup> p-

352 value=ns; untreated vs. PEDF<sup>KO/KO</sup> \*\*p-value <0.01; PEDF<sup>+/+</sup> vs PEDF<sup>KO/KO</sup> \*\*p-value<0.01. untreated  
353 n=3, PEDF<sup>+/+</sup> n=4, PEDF<sup>KO/KO</sup> n=3.) This data suggests that loss of PEDF increased regional loss of  
354 photoreceptors after light damage.

355

356 **5.4.4 Figure 4: PEDF<sup>KO/KO</sup> animals' RPE fails to increase rhodopsin metabolism after light**  
357 **damage.**

358 Loss of PEDF in the RPE affects aging and RPE functional deficiency<sup>2,51</sup>. To assess changes in RPE  
359 function in the absence of PEDF, we performed a rhodopsin metabolism assay as a proxy for RPE  
360 phagocytic capacity, a critical function of the RPE. We found that at day seven after LIRD, PEDF<sup>+/+</sup>  
361 animals significantly increased rhodopsin metabolism in response to damage. However, PEDF<sup>KO/KO</sup> mice  
362 failed to significantly increase rhodopsin metabolism, although they showed increased damage compared  
363 to wild-type littermate controls (See Figure 4F; quantified in Fig. 4G: Two-way ANOVA with Tukey's  
364 multiple comparison test, \*p-value<0.05). Defects in phagocytosis of PEDF<sup>KO/KO</sup> mice have been  
365 previously documented<sup>10</sup>. These data suggest that loss of PEDF results in reduced capacity for  
366 phagocytosis by the RPE.

367

368 **5.4.5 Figure 5: PEDF<sup>KO/KO</sup> results in loss of retinal function following light stress**

369 We also assessed for functional changes using electroretinograms to accompany the distinctive in vivo  
370 and post-mortem histology analysis that we performed. Under scotopic conditions, we found that at  
371 baseline until three days post-LIRD, there was no significant difference between genotypes in either a- or  
372 b-wave function. However, by days 5 and 7, there were significant defects in a- and b-wave amplitudes of  
373 PEDF<sup>KO/KO</sup> compared to wild-type littermates (Fig. 3A-B: Two-way ANOVA with Sidak's Multiple  
374 comparison correction. Scotopic a-wave- Day 5: PEDF<sup>+/+</sup> vs. PEDF<sup>KO/KO</sup> \*\*p-value<0.01. Day 7: \*\*p-  
375 value<0.01 n=3-7/group/timepoint. Scotopic b-wave: Day 5: \*p-value<0.05. Day 7: \*p-value<0.05). To  
376 accompany the rhodopsin metabolism analysis, we used c-wave analysis as a proxy to evaluate the RPE  
377 function. We found that after light damage, there is not a significant difference between PEDF<sup>+/+</sup> and

378 PEDF<sup>KO/KO</sup> animals until day seven post-LIRD damage (Fig5.C: Two-way ANOVA with Sidak's multiple  
379 comparison correction: PEDF<sup>+/+</sup> vs. PEDF<sup>KO/KO</sup>; Day 5-ns; Day 7 \*p-value<0.05). This datum aligns with  
380 the functional deficits observed in the RPE in our immunofluorescence data from Figure 4. We also  
381 assessed the scotopic and photopic waveforms of PEDF<sup>KO/KO</sup> compared to PEDF<sup>+/+</sup> at baseline and day  
382 seven post-LIRD. PEDF<sup>KO/KO</sup> animals have a slightly lower b-wave and c-wave amplitude compared to  
383 PEDF<sup>+/+</sup> littermate controls at baseline (Fig.5D); however, there were no defects in photopic function  
384 (Fig. 5F). At day seven after damage, both scotopic and photopic waveforms worsened in PEDF<sup>KO/KO</sup>  
385 animals compared to PEDF<sup>+/+</sup> animals (Fig. 5E and 5G). These data suggest that the loss of PEDF  
386 negatively affects the retina and RPE function and leads to increased damage after LIRD compared to  
387 PEDF<sup>+/+</sup> littermates.

388

#### 389 **5.4.6 Figure 6: PEDF<sup>KO/KO</sup> Results in Suppression of the Damaged-Associated Increase in IGF1** 390 **Expression after Light Damage**

391 Studies of hypoxic trauma, diabetic retinopathy, and pharmacological damage in the eye have linked the  
392 expression of PEDF and insulin-like growth factor 1(IGF-1) to the protection of RPE cells and other  
393 ocular structures after insult<sup>52-54</sup>. To determine if loss of PEDF impacts the expression of IGF-1 after  
394 damage, we used immunofluorescence to stain retinal sections of PEDF<sup>+/+</sup> and PEDF<sup>KO/KO</sup> animals. We  
395 quantified the expression of IGF-1 from baseline until day seven post-damage. Notably, PEDF<sup>KO/KO</sup>  
396 animals showed significant reductions in IGF-1 starting at day three compared to wildtype littermates (  
397 Fig 6Q: Two-way ANOVA with Tukey's multiple comparison test, n=3-4 animals/group/timepoint. Day 3:  
398 \*\*\*\*p-value<0.0001; Day 5: \*\*\*\*<0.0001; Day 7: \*\*\*\*p-value<0.0001). Increased infiltrating galectin-3  
399 positive immune cells were found at the RPE-photoreceptor interface in PEDF<sup>KO/KO</sup> animals and  
400 significantly more damage via loss of ONL thickness compared to wildtype littermates (See Fig. 6A-P).  
401 To confirm these findings, we tested the protein expression of IGF-1 in PEDF<sup>+/+</sup> and PEDF<sup>KO/KO</sup> animals.  
402 At baseline, there is no significant difference in IGF-1 expression among PEDF<sup>+/+</sup> and PEDF<sup>KO/KO</sup>  
403 animals (Two-way ANOVA with Tukey's multiple comparison test. N=3-6 animals/group/timepoint.

404 Baseline: PEDF  $+/+$  vs. PEDF  $KO/KO$  =ns). PEDF  $+/+$  animals significantly increased IGF-1 expression  
405 by day seven after damage (PEDF  $+/+$  no damage vs. PEDF  $+/+$  Day 7 post \*p-value<0.05). Notably, the  
406 expression of IGF-1 in response to damage was significantly dampened in PEDF  $KO/KO$  compared to PEDF  
407  $+/+$  animals at day 7 (PEDF  $+/+$  Day 7 vs. PEDF  $KO/KO$  Day 7 \*\*p-value<0.01). Immune cells, like  
408 microglia, with high expression of IGF1 are associated with neuroprotection<sup>55,56</sup>. We found that subretinal  
409 immune cells in the PEDF  $+/+$  animals on day 7 showed a prominent expression of IGF1 in the cell  
410 body/cytoplasm. However, the subretinal immune cells in the PEDF  $KO/KO$  had very little to no expression  
411 of IGF-1. These data may suggest that loss of PEDF results in global loss of IGF-1 expression and  
412 increased recruitment of IGF-1 deficient immune cells.

413

#### 414 **5.4.7 Figure 7: Loss of PEDF results in robust inflammatory response compared to wildtype** 415 **controls**

416 Pigment epithelium-derived factor regulates inflammatory responses in multiple diseases, including  
417 diabetic retinopathy, dry eye disease, and cancer studies<sup>17,21,57-61</sup>. Specifically, the 44-mer and 17-mer  
418 PEDF peptides have been associated with antagonizing IL-6 production, thus suppressing chorioretinal  
419 inflammation<sup>62</sup>. We used immunofluorescence staining of RPE flat mounts to evaluate how the loss of  
420 PEDF affects the recruitment of subretinal immune cells at different time points after LIRD. The number  
421 of subretinal immune cells in PEDF  $KO/KO$  and wildtype littermates is comparable at baseline. However,  
422 after LIRD, PEDF  $KO/KO$  animals had significantly more recruitment of subretinal immune cells by day  
423 five than wildtype littermates (See Fig. 7A-D; quantified in Fig. 7E: Two-way ANOVA with Sidak's  
424 multiple comparison test, Day 5: PEDF  $+/+$  vs. PEDF  $KO/KO$  \*\*p-value 0.01). The number of subretinal  
425 immune cells peaked on day 7 (\*\*\*\*p-value 0.0001). Additionally, the cells had higher expression of  
426 galectin-3, a pleiotropic,  $\beta$ -galactoside-binding protein associated with reactive microglia, compared to  
427 wildtype littermate controls at day seven post<sup>33</sup>.

428

#### 429 **5.4.8 Figure 8: Loss of PEDF differentially affects Lgals and Nlrp3 gene expression**

430 To determine if loss of PEDF differentially affects inflammasome activation after LIRD, we first used  
431 digital drop PCR to assess mRNA expression of both *Lgals3* and *Nlrp3* in both the retina (data not shown)  
432 and RPE. *Lgals3*, the gene that encodes galectin-3, mRNA expression was significantly lower in the RPE  
433 of PEDF<sup>KO/KO</sup> animals compared to wildtype littermate controls at baseline (Two-way ANOVA with  
434 Tukey's multiple comparison test. \*p-value<0.05). However, the amount of the transcript significantly  
435 increases on day 7 in PEDF<sup>KO/KO</sup> animals compared to wildtype littermates at the same time point (\*\*p-  
436 value< 0.01). Additionally, *Nlrp3* mRNA in the RPE only increased significantly at day seven post-LIRD  
437 in PEDF<sup>KO/KO</sup> compared to wildtype littermates (\*p-value<0.05). The supplemental information can find  
438 the mRNA expression of *LGALS3* and *NLRP3* in RPE and *SNAI1*, *IL-6*, and *IL1-beta* expression in  
439 retina and RPE. The loss of PEDF differentially regulates genes that encode galectin-3 and  
440 inflammasome-associated protein, *Nlrp3*, at baseline and after LIRD, implicating PEDF in regulating  
441 galectin-3 gene expression.

442

#### 443 **5.4.9 Figure 9: Loss of PEDF reduces total Galectin-3 expression**

444 Previous studies have identified immune cells recruited to the subretinal space as a unique subset enriched  
445 for galectin-3<sup>63,64</sup>. To investigate the relationship between the loss of PEDF and galectin-3 expression, we  
446 performed protein expression analysis via western blot at baseline and day seven post-LIRD in PEDF  
447 <sup>KO/KO</sup> compared to PEDF<sup>+/+</sup>. PEDF<sup>KO/KO</sup> animals, at baseline, had significantly lower galectin-3 protein  
448 expression than those of PEDF<sup>+/+</sup> littermate controls (PEDF<sup>+/+</sup> vs. PEDF<sup>KO/KO</sup> Baseline \*\*\*\*p-  
449 value<0.0001). This data substantiated results from Figure 8A, which showed lower *Lgals3* mRNA  
450 expression in PEDF<sup>KO/KO</sup> animals at baseline. However, while the level of galectin-3 protein expression  
451 in PEDF<sup>KO/KO</sup> animals increases after phototoxic damage, it remains suboptimal to PEDF<sup>+/+</sup> animals at  
452 the same time point (Two-way ANOVA with Tukey multiple comparison test, n=3/group/timepoint.  
453 PEDF<sup>+/+</sup> vs PEDF<sup>KO/KO</sup> Day 7 \*\*\*p-value 0.001). These data suggest the loss of PEDF significantly  
454 affects the protein expression of Galectin-3 both before and after LIRD.

455

456 **5.4.10 Figure 10: Inhibition of Galectin-3 with TD139 significantly decreases PEDF levels after**  
457 **light damage**

458 Previous studies have correlated increased expression of galectin-3 with poor clinical outcomes in  
459 multiple eye diseases<sup>65-70</sup>. Additionally, the inhibition galectin-3 by genetic manipulation or  
460 pharmacological targeting dampened immune cell activity<sup>71</sup>. To determine if dampening the galectin-3  
461 expression would be protective after LIRD damage, we pharmacologically inhibited Galectin-3 in PEDF  
462 <sup>+/+</sup> animals using TD139 to determine if inhibiting galectin-3 was protective after LIRD. We found that  
463 treatment with galectin-3 inhibitor (TD139) did not significantly affect galectin-3 protein levels.  
464 However, we did notice significant differences in the visual function of animals without LIRD exposure  
465 (data not shown). Interestingly, we found that animals treated with galectin-3 inhibitor had a worse  
466 damage phenotype than LIRD-only controls. Surprisingly, PEDF levels in animals treated with TD139  
467 and LIRD were significantly lower than in the LIRD-only control group (One-way ANOVA with Tukey's  
468 multiple comparison test. n=3 animals/group. PEDF <sup>+/+</sup> No damage vs. PEDF <sup>+/+</sup> LIRD only: p-value=ns;  
469 PEDF <sup>+/+</sup> no damage vs. PEDF <sup>+/+</sup> LIRD + Gal-3 inhibitor \*\*\*p-value<0.001; PEDF <sup>+/+</sup> LIRD only vs.  
470 PEDF <sup>+/+</sup> LIRD + Gal-3 inhibitor \*p-value<0.01). Treatment with TD139 alone does not affect visual  
471 function or Galectin-3 protein expression compared to vehicle only(See Supplemental Figure 1). These  
472 data suggest a potential correlation between PEDF and Galectin-3 expression since inhibition of galectin-  
473 3 significantly decreases PEDF expression.

474

475 **5.5 DISCUSSION**

476

477 The findings from this study reveal that PEDF plays a significant regulatory role in facilitating immune  
478 privilege and suppressing inflammation to protect vulnerable tissues from damage within the ocular  
479 microenvironment. Previous studies have evaluated and purported the protective role of PEDF against  
480 photoreceptor death in albino rat models under various light damage conditions; these studies showed that  
481 intravitreal supplementation with exogenous PEDF was protective; however, the mechanism for this

482 protection was not established<sup>72,73</sup>. These studies were limited in that they used albino animals, which are  
483 not as translatable to normal vision in humans, and they used This study aimed to examine the influence  
484 of PEDF on the outcome of visual function, galectin-3 positive subretinal immune cell recruitment, and  
485 effects on the neurotrophic factor, IGF-1, after light damage. By employing a global deletion model of  
486 PEDF and comparing the multiple visual metrics to wildtype controls, we could identify phenotypic shifts  
487 during damage resolution that coincide with expression changes in IGF-1 and Galectin-3. Studying these  
488 molecular mechanisms may be the basis for better understanding and predicting the pathological onset of  
489 disease, reveal new pathway interactions for conserved biomarkers, and present new considerations for  
490 therapeutic approaches employing gene therapy. To our knowledge, our study is the first to evaluate the  
491 potential regulatory axis of PEDF-Galectin-3-IGF-1 in visual function. Additionally, according to our  
492 understanding, this is the first study to implicate PEDF in the modulation of galectin-3 expression in the  
493 eye. Overall, our results implicate the loss of PEDF as an essential regulator of both IGF-1 and Galectin-3  
494 expression after light damage, suggesting an additional level of RPE-mediated regulation of  
495 immunosuppression in the ocular microenvironment.

496

497

498 Immune privilege in the eye requires an intact RPE monolayer, which secretes factors that suppress the  
499 immune response, controls the maturation of immune cells, and leads to apoptosis of infiltrating  
500 macrophages, magnifying the role of RPE in facilitating immunomodulation<sup>74-81</sup>. Studies of pigment  
501 epithelia derived from various ocular tissues suggest that immunosuppression is achieved by cell-cell  
502 contact, soluble factors, or both 240, depending on the source of epithelia. The retinal pigment epithelia  
503 predominantly utilize secreted, soluble factors to suppress immune cell activation. Previous studies have  
504 described the immunomodulatory functions of the RPE via the secretion of cytokines and neuropeptides,  
505 like alpha-macrophage stimulating hormone( $\alpha$ -MSH) and Neuropeptide Y(NPY)<sup>79,81-83</sup>. However, the  
506 complete mechanism by which the RPE participates in immunomodulation has not been fully elucidated.

507

508  
509 Loss of PEDF is associated with aging and reductions in RPE functionality<sup>11,84</sup>. Here, we accessed the  
510 potential immunomodulatory effects of the secreted homeostatic marker, PEDF, on damage outcomes and  
511 inflammation. Previous studies have described overexpression of or supplementation with PEDF as  
512 protective of photoreceptors and motor neurons, improvements in mitochondrial function and cortical  
513 neurons after damage, and inhibition of inflammatory damage<sup>2,22,45,85-88</sup>. Additionally, deletion of PEDF  
514 is associated with aging, increased inflammation, and increased loss of visual function<sup>3,20,24,89</sup>. Our results  
515 confirm the findings of other studies since the loss of PEDF resulted in increased retinal thinning, more  
516 damage-associated auto-fluorescent dots at the RPE-photoreceptor interface, significant loss of the  
517 photoreceptor layer, and increased cell death compared to littermate controls.  
518 Additionally, when evaluating the retinal function, we found that the RPE of PEDF<sup>KO/KO</sup> animals had a  
519 reduced capacity for rhodopsin metabolism after LIRD compared to littermate controls at the same time  
520 point. Retinal function loss reduced scotopic *a*-, *b*, and *c*-wave amplitudes by five to seven days after light  
521 damage in PEDF<sup>KO/KO</sup> animals compared to littermate controls. These data suggest that PEDF is  
522 protective against excessive damage after phototoxic light exposure.

523  
524  
525 The RPE is the major contributor to IGF-1 secretion in the ocular environment<sup>90</sup>. The importance of IGF-  
526 1 as a neurotropic factor and a regulator of immune cell function has been described in the eye and other  
527 tissue types under normal and pathological conditions, like cancer and ischemia<sup>53,55,56,91-93</sup>. Additionally,  
528 decreases in IGF-1 expression have been correlated with aging, increased damage, and apoptosis in eye  
529 and brain studies<sup>94-96</sup>. To assess how the loss of PEDF may affect the expression and abundance of the  
530 neurotrophic factor, IGF-1, we first evaluated IGF-1 immunoreactivity in retinal sections of PEDF<sup>KO/KO</sup>  
531 animals compared to PEDF<sup>+/+</sup> animals at baseline. Baseline data showed no significant changes in IGF-1  
532 expression between genotypes. However, after insult, there was a considerable loss in IGF-1 expression  
533 beginning on Day 3 of PEDF<sup>KO/KO</sup> animals, which increased to Day 7. We confirmed these findings via



534 western blot analysis, showing a significant reduction in IGF1 protein expression in PEDF<sup>KO/KO</sup>  
535 compared to wild-type littermates at day 7. IGF-1 inhibits apoptosis of photoreceptors via the  
536 downregulation of caspase-3 and c-JUN signaling; thus, the reduced expression of IGF-1 may explain the  
537 increased degree of apoptosis observed in Fig.3B<sup>53,95,96</sup>. The presence of IGF-1 and Galectin-3 co-  
538 expression in neuroprotective immune cells has been reported previously<sup>55,56,97</sup>. We also assessed the  
539 presence of IGF-1 in recruited subretinal immune cells adhered to RPE flat mounts collected from PEDF  
540<sup>+/+</sup> and PEDF<sup>KO/KO</sup> animals at day seven post-LIRD. We found that PEDF<sup>KO/KO</sup> animals had fewer IGF-1  
541 positive immune cells (See Fig. 6W-Y) compared to the PEDF<sup>+/+</sup>(Fig.6T-V) at the same time point. IGF-1  
542 modulates macrophage responsiveness and activity when challenged with a high-fat diet, shifting the  
543 transcriptional and morphological phenotypes to that of an M2-like proinflammatory macrophage<sup>98</sup>. A  
544 decrease in IGF-1 and PEDF expression has also been described in aging studies, which may suggest a  
545 similar mechanism as observed during our light damage experiments in the absence of PEDF<sup>99-102</sup>. The  
546 loss of IGF-1 expression with age likely affects microglia function and sensitivity. The loss of PEDF leads  
547 to insult-initiated down-regulation of IGF-1 protein expression and reduced recruitment of IGF-1-  
548 expressing immune cells.

549

550

551 Multiple groups have described a unique subclass of immune cells enriched in galectin-3, recruited during  
552 neurodegeneration in the brain and the eye<sup>33,97,103-106</sup>. In the eye, galectin-3 enriched subretinal immune  
553 cells are recruited to the photoreceptor-RPE interface, suggesting that there may be a functional  
554 requirement for galectin-3 in the subretinal space<sup>64,105,106</sup>. Elevated galectin-3 expression is associated  
555 with poor prognostic outcomes<sup>65-67,70</sup>. Additionally, an ocular proteome study comparing AMD patients to  
556 age-matched controls found a significant increase in the secretion of galectin-3 binding protein and  
557 pigment epithelium-derived factor from the RPE<sup>107</sup>. However, the correlation between PEDF expression,  
558 Galectin-3 levels, and damage outcomes has yet to be investigated. We hypothesized that loss of PEDF  
559 will increase galectin-3 expressing cells and global expression of galectin-3, ultimately leading to


560 increased inflammation in the ocular microenvironment. To evaluate this, we quantified the number of  
561 galectin-3 expressing cells that adhered to the RPE at baseline and day seven between PEDF<sup>KO/KO</sup>  
562 compared to littermate controls. At baseline, there was no difference between genotypes. However, after  
563 damage, we found that the total number of galectin-3 positive cells was significantly increased in PEDF  
564<sup>KO/KO</sup> animals compared to wildtype controls (See Fig. 7A-E), suggesting that without damage, there is no  
565 increased infiltration of immune cells. However, after damage initiation, PEDF<sup>KO/KO</sup> animals had  
566 significantly more galectin-3 expressing cells infiltrating the subretinal space compared to wild-type  
567 littermates at the same time. Damage to the subretinal space, neurodegeneration, and aging are associated  
568 with an increased activation of inflammation signaling and recruitment of immune cells<sup>108-114</sup>. To  
569 investigate if PEDF<sup>KO/KO</sup> animals exhibit differential expression of galectin-3 and inflammasome  
570 mediator NLRP3, we used digital drop PCR. We found that galectin-3 mRNA expression in the RPE from  
571 PEDF<sup>KO/KO</sup> was significantly reduced compared to wild-type littermates. However, after damage, there is  
572 a significant increase in Lgals3 and NLRP3 expression at day 7 in PEDF<sup>KO/KO</sup> animals compared to the  
573 wildtype controls, which dampens the expression of these genes at the same time point. In agreement  
574 with the gene expression data, galectin-3 protein expression was significantly lower in PEDF<sup>KO/KO</sup>  
575 animals compared to PEDF<sup>+/+</sup>. On day 7, post-damage, PEDF<sup>+/+</sup> animals reduced galectin-3 expression  
576 considerably compared to baseline expression; conversely, galectin-3 increased in the PEDF<sup>KO/KO</sup> animals  
577 at the same time point. Notably, while galectin-3 protein expression in PEDF<sup>KO/KO</sup> animals increased over  
578 baseline expression, there was significantly lower expression of galectin-3 protein at day seven compared  
579 to PEDF<sup>+/+</sup>. These data may suggest that loss of PEDF affects the steady state of galectin-3 expression.  
580 Interestingly, when we pharmacologically inhibited galectin-3 activity in PEDF<sup>+/+</sup> animals during LIRD,  
581 we found it significantly decreased PEDF levels compared to LIRD-only controls (see Fig. 10), leading to  
582 poorer visual outcomes (data not shown). These data suggest that PEDF protects ocular function after  
583 LIRD via a novel galectin-3-mediated mechanism.  
584  
585

586 PEDF suppresses eye diseases and cancer studies<sup>58,59,115</sup>. In this study, we hypothesized that the protective  
587 role of PEDF in the ocular microenvironment after damage includes regulation of inflammation and  
588 immune privilege via galectin-3 mediated signaling. This study reports a putative relationship between  
589 galectin-3 and PEDF, suggesting that galectin-3 enriched immune cells within the subretinal space are a  
590 positive regulator of PEDF expression after light damage. However, the precise molecular signaling by  
591 which loss of PEDF impacts Galectin-3 and IGF-1 expression requires further study.  
592

593 **5.6 Acknowledgments:** Supported by Grants from the National Institutes of Health (R01EY028450,  
594 R01EY021592, P30EY006360, U01CA242936, R01EY028859, T32EY07092, T32GM008490); by  
595 the Abraham J. and Phyllis Katz Foundation; by grants from the U.S. Department of Veterans Affairs  
596 and Atlanta Veterans Administration Center for Excellence in Vision and Neurocognitive  
597 Rehabilitation (RR&D I01RX002806, I21RX001924; VA RR&D C9246C); and an unrestricted grant  
598 to the Department of Ophthalmology at Emory University from Research to Prevent Blindness, Inc.  
599 We would also like to thank Dr. Hans Grossniklaus and Dr. Sue Crawford at Northwestern  
600 University Feinberg School of Medicine for gifting the PEDF knockout mice used in this study.  
601

602 5.7 FIGURES AND TABLES

603 5.7.1 Figure 1: Loss of Pigment Epithelium Derived Factor Modifies Sensitivity to Phototoxic  
604 Damage in C57BL/6J Animals



605

606 Fundus and retinal C57BL/6J animals that express wild-type PEDF (PEDF +/+) or PEDF knockout

607 (PEDF KO/KO) animals are shown. Figure 1A shows Spectral Domain Optical Coherence

608 Tomography (SD-OCT) images of the Fundus and circular B-scans of the retinal architecture around

609 the optic nerve. Top row: PEDF +/+ animals are shown in the top row at both baselines and on day

610 seven post-LIRD. Bottom row: PEDF KO/KO animals at baseline and Day 7 Post LIRD. White

611 arrows denote regions of damage-associated mottling of the fundus. Figure 1B shows the

612 quantification of total retinal thickness and the thickness of the photoreceptor layer of PEDF +/+


613 n=5, PEDF KO/+ n=4, PEDF KO/KO= n=4 at Day 7 Post LIRD. One-way ANOVA Brown-Forsythe

614 test with Barlett's correction. \* p-value< 0.05, \*\* p-value<0.01, \*\*\* p-value<0.001, \*\*\*\* p-

615 value<0.0001.

616

617 **5.7.2 Figure 2: Loss of PEDF Increases Damaged-Associated Autofluorescent Dots at the Level of**  
618 **the RPE**  
619





620



621 Heidelberg Spectralis cSLO (confocal scanning laser ophthalmoscope) images show an increased  
622 accumulation of autofluorescent dots/granules at the level of the photoreceptor-RPE interface after  
623 phototoxic damage that is not present at baseline. Images were taken at -12 diopters at the level of the  
624 interdigitations of RPE and photoreceptors using both the infrared (to detect vascular architecture) and the  
625 blue autofluorescence filter (to detect fluorescent dots). Representative Images at baseline for PEDF  
626 <sup>+/+</sup>(2A-B) and PEDF <sup>KO/KO</sup> (2F-G) and at Day 7 Post LIRD (PEDF <sup>+/+</sup>: 2C-E; PEDF <sup>KO/KO</sup>: 2H-J). A Zoom  
627 (red box) of each representative image with red arrows highlighting individual dots.

628

629 **5.7.3 Figure 3: Loss of PEDF Results in Regional Damage and Increases Apoptosis of**  
 630 **Photoreceptor Cells.**



631




632

633 The morphology of the postmortem tissue shows significant regional alterations in retinal architecture.  
 634 Figure 3A-B shows a representative image of PEDF<sup>+/+</sup> with no damage and day seven post-LIRD.  
 635 Representative images of PEDF<sup>KO/KO</sup> animals with no damage(Figure 2C) and day seven post-damage  
 636 (Figure 2D) are shown. Figure 2D shows severe loss of the outer nuclear layer (ONL), disruption of the  
 637 photoreceptor inner and outer segment layer, and aberrations in the RPE monolayer in PEDF<sup>KO/KO</sup>  
 638 compared to PEDF<sup>+/+</sup> controls at day five post-light damage. Figure 3E quantifies ONL counts from -  
 639 1750 microns(superior) to 1750 microns (inferior) on either side of the optic nerve. The damage is

640 regionally isolated to the superior portion of the retina and is significantly between PEDF KO/KO n=4  
641 and PEDF <sup>+/+</sup> n=4. One-way ANOVA with Brown-Forsythe test and Barlett's correction. # p-value<0.05,  
642 ## p-value<0.01, ### p-value<0.001, #### p-value <0.0001. The loss trend was the same on day seven  
643 post-LIRD (data not shown).  
644 Figure 3F-N shows representative images of retinal sections stained for TUNEL (green), immune cells via  
645 CX3CR1-GFP (red), and cell nuclei (DAPI) of no damage control (3F-H), Day 7 PEDF <sup>+/+</sup>(3I-K) and,  
646 Day 7 PEDF <sup>KO/KO</sup> (3L-N). These data are quantified in Figure 3O and show that PEDF <sup>KO/KO</sup> have  
647 significantly more TUNEL-positive cells than either the untreated (\*\* p-value<0.01) or the PEDF <sup>+/+</sup> (\*\*  
648 p-value<0.01) group.  
649



650 5.7.4 Figure 4: PEDF<sup>KO/KO</sup> RPE Fail to Increase Rhodopsin Metabolism after Light Damage



651 Rhodopsin, RPE65, DAPI

652 Loss of PEDF results in a suboptimal production of phagosomes by the RPE after light-induced retinal

653 damage. Figure 4A-F shows representative retinal immunofluorescence images of a PEDF<sup>+/+</sup> and

654 PEDF<sup>KO/KO</sup> at day 7 Post-light damage. The sections were stained with Rhodopsin(green) to visualize

655 shed rod outer segments and phagosomes, Best1(red) was used to visualize the RPE monolayer, and cell

656 nuclei were stained with DAPI (blue). Figure 4G, notably, the PEDF<sup>+/+</sup> animals significantly increase

657 production to redress clearance demands at day seven post-LIRD compared to untreated PEDF<sup>+/+</sup> (Two-


658 way ANOVA, Tukey's multiple comparison test, \*p-value < 0.05). However, while PEDF<sup>KO/KO</sup> animals

659 had a more significant accumulation of phagosomes at baseline, they failed to increase phagosome


660 production after light damage.

661

662 **5.7.5 Figure 5 The Loss of PEDF leads to significant deficits in visual function after light damage**  
 663 **exposure.**



664




665

666

667 The figure shows the maximal visual output of *a*-wave, *b*-wave, and *c*-wave at a flash intensity of 10  
668 candelas/second/meters<sup>2</sup> (cd.s/m<sup>2</sup>). These data show no statistically significant difference in the visual  
669 function of the PEDF<sup>KO/KO</sup> compared to PEDF<sup>+/+</sup> at baseline or on day three after light damage.  
670 However, after day three there is a notable decrease in visual function of PEDF<sup>KO/KO</sup> animals in both *a*-  
671 and *b*-wave amplitudes at 10Hz that persists to day 7(*a*-wave: day 5: \*\* p-value<0.01; day 7: \*\* p-  
672 value<0.01 and *b*-wave: day 5: \*p-value <0.05; day 7: \*p-value<0.05. n=3-7/time point/group) see Figure  
673 5A and 5B; Two-way ANOVA with Sidak's multiple comparison correction). Significant loss of the *c*-  
674 wave amplitudes is delayed to day seven post-light damage (See Fig. 2C: Two-way ANOVA with Sidak's  
675 multiple comparison corrections, day 7: \* p-value<0.01). The scotopic waveforms of PEDF KO/KO mice  
676 also reveal a slight depression in the waveform amplitude at baseline compared to PEDF<sup>+/+</sup> (n=3-  
677 4/genotype). This reduction in waveform amplitude is more pronounced at day seven post-LIRD  
678 (n=5/genotype; See Figures 5D and 5E). Photopic waveforms show a similar trend as scotopic waveforms  
679 with significantly reduced amplitudes in PEDF KO/KO at day 7 compared to PEDF<sup>+/+</sup> littermates (See  
680 Fig. 5F-G).  
681

682 **5.7.6 Figure 6: Loss of PEDF Suppresses the Damage-Associated Increase in IGF-1 after Light**  
 683 **Damage**  
 684




685

686

687 Retinal sections were collected at days 3, 5, and 7 post light damage and stained for the neurotrophic  
 688 factor, IGF-1 (red), the immune cell marker, IBA1 (green), immune cell activation marker, Galectin-  
 689 3 (white), and dapi (blue). Staining showed that at baseline, there was no significant difference between  
 690 PEDF<sup>+/+</sup> and PEDF<sup>KO/KO</sup> animals without damage. Figure 6A-P is a representative image showing the  
 691 degree of expression of IGF-1 and Galectin-3 and the infiltration of immune cells from the retina to the  
 692 subretinal space. After light damage, there is an increase in Galectin-3 positive cell expression in both

693 genotypes at day 3, with the earliest deposition at the photoreceptor-RPE interface occurring at day 3. By  
694 day 7, only the PEDF<sup>KO/KO</sup> animals still have Galectin-3 positive cells at the interface of the  
695 photoreceptors-RPE. Additionally, when quantifying the immunofluorescent signal of IGF-1, there are  
696 statically significant differences between the PEDF<sup>+/+</sup> and PEDF<sup>KO/KO</sup> as early as day 3. The levels of  
697 IGF-1 continue to decrease until day seven post LIRD (see Fig. 6Q). Analysis: Two-way ANOVA with  
698 Tukey's multiple comparison test, n=3-5/ group/time point. \* p-value< 0.05, \*\* p-value<0.01, \*\*\* p-  
699 value<0.001, \*\*\*\* p-value<0.0001. In Figure 6R, we confirm this finding via total eye cup expression of  
700 IGF-1 normalized to GAPDH in no damage controls versus at day seven post-LIRD via western blot.  
701 Figure 6R quantifies the total expression of IGF-1 between PEDF<sup>+/+</sup> and PEDF<sup>KO/KO</sup> before and after  
702 LIRD. Analysis: Two-way ANOVA with Tukey's multiple comparison test, n=3-6/group/timepoint.  
703 Subretinal immune cells recruited to RPE in PEDF<sup>KO/KO</sup> have lower expression of IGF-1 than PEDF<sup>+/+</sup>  
704 animals. Figure 6T-Y shows a representative image of PEDF<sup>+/+</sup>( 6T-V) and PEDF<sup>KO/KO</sup> (6W-Y) stained  
705 for ZO1(blue), IGF-1(red), and CX3CR1-GFP (green) to look for heterogeneity in the immune cell  
706 population.  
707

708 **5.7.7 Figure 7: Loss of PEDF increases infiltration of galectin-3<sup>+</sup> immune cells**  
709 **compared to PEDF<sup>+/+</sup>**




710

711 We collected RPE flat mounts to assess if PEDF<sup>KO/KO</sup> animals showed an increased inflammatory profile  
712 and stained them for Galectin-3 (red) and CX3CR1-GFP(Green). We found that PEDF<sup>KO/KO</sup> animals were  
713 like PEDF<sup>+/+</sup> animals at baseline and up to day three post-LIRD damage. However, by day 5, there was  
714 the inflammation phenotype significantly increased in PEDF<sup>KO/KO</sup> animals compared to littermate  
715 controls \* p-value < 0.05, \*\* p-value < 0.01, \*\*\* p-value < 0.001, \*\*\*\* p-value < 0.0001 (Analysis: Two-way  
716 ANOVA with sidak's multiple comparison correction. N=3-5 animals group/ time point. p-value: Day 5:  
717 \*\* vs Day 7 \*\*). Figure 7A-D shows a representative image of the subretinal immune cell morphology in  
718 PEDF<sup>+/+</sup> and PEDF<sup>KO/KO</sup> animals at baseline and Day 7. Figure 7E shows the total number of Gal-3  
719 positive cells counted from baseline to day seven post-LIRD between PEDF<sup>+/+</sup> and PEDF<sup>KO/KO</sup>

720

721 **5.7.8 Figure 8: Loss of PEDF Increases Galectin-3 Gene Expression at Day 7 Post LIRD**  
722 **Compared to Wildtype Littermates**



723

724 Retinal and RPE tissues were collected separately, and RNA was extracted from each tissue sample type.

725 Figure 9A quantifies Lgals3 and Nlrp3 gene expression normalized to HRPT in the retina between PEDF

726 +/+ and PEDF<sup>KO/KO</sup> at baseline and Day 7 Post LIRD. Figure 9A-B shows the gene expression of Lgals3

727 and Nlrp3 at the same time points in the RPE. The Lgals3 expression in the RPE Two-way ANOVA;

728 PEDF<sup>KO/KO</sup> baseline vs. PEDF KO/KO Day 7: \*p-value<0.05; PEDF<sup>+/+</sup> Day 7 vs. PEDF<sup>KO/KO</sup> Day 7: \*p-


729 value<0.05. However, only at day 7 in the RPE is Nlrp3 expression significantly different in the PEDF

730 <sup>KO/KO</sup> compared to littermate controls(\*p-value<0.05).


731

732 **5.7.9 Figure 9: Loss of PEDF Reduces Total Galectin-3 Expression Before and After LIRD**

A



B




733

734 PEDF<sup>KO/KO</sup> animals have significantly lower expression of Galectin-3 at baseline compared to littermate  
735 controls. Additionally, after damage, there is a suboptimal increase in Galectin-3 protein expression on  
736 day seven post-LIRD. PEDF<sup>+/+</sup> animals dampen galectin-3 expression in response to LIRD damage at  
737 day 7, suggesting differential temporal regulation of the protein when PEDF is present compared to when  
738 it is not. Figure 9A shows a western blot that was probed for PEDF (50kDa), Galectin-3 (~30kDa), and  
739 GAPDH (~37kDa) loading control. The results from Figure 9A are quantified in Figure 9B and show that  
740 there are significant differences in Galectin-3 expression at both baselines (Two-way ANOVA with  
741 Tukey's multiple comparison correction. \*\*\*\* p-value<0.0001. sample sizes: 3 animals/group/time point)  
742 and at Day 7 (\*\*\*\*p-value<0.0001) between PEDF<sup>KO/KO</sup> and PEDF<sup>+/+</sup> animals. While Galectin-3  
743 expression increases in the PEDF<sup>KO/KO</sup> animals at day seven compared to baseline, it is still dampened  
744 compared to the Gal-3 expression of PEDF<sup>+/+</sup> at the same time point.


745



746 5.7.10 **Figure 10: Treatment with Galectin-3 inhibitor, TD139, significantly decreases PEDF**  
747 **expression in PEDF<sup>+/+</sup> animals after LIRD.**




Galectin-3 Inhibitor experiment



748

C




749


750 Figure 10A shows a western blot exhibiting that PEDF<sup>+/+</sup> with no damage controls have high levels  
751 of PEDF, and exposing PEDF<sup>+/+</sup> animals to LIRD shows a decrease in PEDF levels. Still, it is not  
752 significantly different from no-damage controls. However, by adding the galectin-3 inhibitor to  
753 LIRD, there is a significant loss of PEDF compared to LIRD, and there is no damage control. 10B is  
754 a quantification of 10A. (One-way ANOVA with Tukey's multiple comparison test. No damage vs.

755 LIRD only (Day 5 post) ns; not significant. No damage vs. LIRD (day 5) + Gal-3 inhibitor \*\*\*p-  
756 value<0.001. LIRD only (Day 5) vs. LIRD (Day 5) + Gal-3 inhibitor (\*p-value<0.05). 10C shows  
757 representative fundus and retinal images taken using SD-OCT, displaying the effects of TD139  
758 treatment with and without LIRD. Treatment with an inhibitor in conjunction with LIRD  
759 significantly increased retinal thinning compared to the control of LIRD only. Note: TD139  
760 treatment alone does not affect visual function Galectin-3 expression levels ( Supplemental Figure  
761 1).  
762

763 5.7.11 Figure 11: Schematic of Model Summary



764



765

766 Fig 11A: Schematic summary illustrating significant differences between PEDF<sup>+/+</sup> and PEDF<sup>KO/KO</sup>

767 animals and the impacts on IGF-1 and Galectin-3 expression.

768 Fig 11B: Shows the proposed immunomodulatory network influencing photoreceptor death, immune

769 cells, and RPE cells. Images made using Biorender.

770

771 **5.8 References**

772

- 773 1 Jablonski MM, Tombran-Tink J, Mrazek DA, Iannaccone A. Pigment Epithelium-Derived  
774 Factor Supports Normal Development of Photoreceptor Neurons and Opsin Expression  
775 after Retinal Pigment Epithelium Removal. *The Journal of Neuroscience* 2000;**20**:7149.  
776 <https://doi.org/10.1523/JNEUROSCI.20-19-07149.2000>.
- 777 2 He Y, Leung KW ah, Ren Y, Pei J, Ge J, Tombran-Tink J. PEDF Improves Mitochondrial  
778 Function in RPE Cells During Oxidative Stress. *Invest Ophthalmol Vis Sci* 2014;**55**:6742–  
779 55. <https://doi.org/10.1167/IOVS.14-14696>.
- 780 3 Dixit S, Polato F, Samardzija M, Abu-Asab M, Grimm C, Crawford SE, *et al*. PEDF  
781 deficiency increases the susceptibility of rd10 mice to retinal degeneration. *Exp Eye Res*  
782 2020;**198**:108121. <https://doi.org/10.1016/J.EXER.2020.108121>.
- 783 4 Tombran-Tink J, Mazuruk K, Rodriguez IR, Chung D, Linker T, Englander E, *et al*.  
784 *Organization, Evolutionary Conservation, Expression and Unusual Alu Density of the*  
785 *Human Gene for Pigment Epithelium-Derived Factor; a Unique Neurotrophic Serpin*.  
786 Molecular Vision. 1996. URL: <http://www.molvis.org/molvis/v2/a11/> (Accessed 22 July  
787 2024).
- 788 5 Raymond SM, Jackson IJ. The retinal pigmented epithelium is required for development  
789 and maintenance of the mouse neural retina. *Current Biology* 1995;**5**:1286–95.  
790 [https://doi.org/10.1016/S0960-9822\(95\)00255-7](https://doi.org/10.1016/S0960-9822(95)00255-7).
- 791 6 Karakousis PC, John SK, Behling K, Surace EM, Smith JE, Hendrickson A, *et al*.  
792 Localization of pigment epithelium derived factor (PEDF) in developing and adult human  
793 ocular tissues. *Mol Vis* 2001;**7**:154–63.
- 794 7 Longbottom R, Fruttiger M, Douglas RH, Martinez-Barbera JP, Greenwood J, Moss SE.  
795 Genetic ablation of retinal pigment epithelial cells reveals the adaptive response of the  
796 epithelium and impact on photoreceptors. *Proc Natl Acad Sci U S A* 2009;**106**:18728–33.  
797 [https://doi.org/10.1073/PNAS.0902593106/SUPPL\\_FILE/0902593106SI.PDF](https://doi.org/10.1073/PNAS.0902593106/SUPPL_FILE/0902593106SI.PDF).
- 798 8 Aymerich, Maria S., Alberdi, EM. , Martinez, A. , Becerra SP. Evidence for pigment  
799 epithelium derived factor receptors in the neural retina. *Invest Ophthalmol Vis Sci*  
800 2001;**42**:3287–93.
- 801 9 Becerra SP, Fariss RN, Wu YQ, Montuenga LM, Wong P, Pfeffer BA. Pigment  
802 epithelium-derived factor in the monkey retinal pigment epithelium and  
803 interphotoreceptor matrix: apical secretion and distribution. *Exp Eye Res* 2004;**78**:223–34.  
804 <https://doi.org/10.1016/J.EXER.2003.10.013>.
- 805 10 Rebutini IT, Crawford SE, Becerra SP. PEDF Deletion Induces Senescence and Defects  
806 in Phagocytosis in the RPE. *International Journal of Molecular Sciences* 2022, Vol 23,  
807 Page 7745 2022;**23**:7745. <https://doi.org/10.3390/IJMS23147745>.
- 808 11 Bhutto IA, McLeod DS, Hasegawa T, Kim SY, Merges C, Tong P, *et al*. Pigment  
809 epithelium-derived factor (PEDF) and vascular endothelial growth factor (VEGF) in aged  
810 human choroid and eyes with age-related macular degeneration. *Exp Eye Res* 2006;**82**:99–  
811 110. <https://doi.org/10.1016/j.exer.2005.05.007>.
- 812 12 Ogata N, Matsuoka M, Imaizumi M, Arichi M, Matsumura M. Decreased levels of  
813 pigment Epithelium-derived factor in eyes with neuroretinal dystrophic diseases. *Am J*  
814 *Ophthalmol* 2004;**137**:1129–30. <https://doi.org/10.1016/j.ajo.2003.11.080>.

- 815 13 Rogers ME, Navarro ID, Perkumas KM, Niere SM, Allingham RR, Crosson CE, *et al.*  
816 Pigment Epithelium-Derived Factor Decreases Outflow Facility. *Invest Ophthalmol Vis*  
817 *Sci* 2013;**54**:6655. <https://doi.org/10.1167/IOVS.13-12766>.
- 818 14 Spranger J, Osterhoff M, Reimann M, Möhlig M, Ristow M, Francis MK, *et al.* Loss of  
819 the Antiangiogenic Pigment Epithelium-Derived Factor in Patients With Angiogenic Eye  
820 Disease. *Diabetes* 2001;**50**:2641–5. <https://doi.org/10.2337/DIABETES.50.12.2641>.
- 821 15 Liu Y, Leo LF, McGregor C, Grivtishvili A, Barnstable CJ, Tombran-Tink J. Pigment  
822 epithelium-derived factor (PEDF) peptide eye drops reduce inflammation, cell death and  
823 vascular leakage in diabetic retinopathy in Ins2(Akita) mice. *Mol Med* 2012;**18**:1387–401.  
824 <https://doi.org/10.2119/MOLMED.2012.00008/FIGURES/12>.
- 825 16 Ma B, Zhou Y, Liu R, Zhang K, Yang T, Hu C, *et al.* Pigment epithelium-derived factor  
826 (PEDF) plays anti-inflammatory roles in the pathogenesis of dry eye disease. *Ocul Surf*  
827 2021;**20**:70–85. <https://doi.org/10.1016/J.JTOS.2020.12.007>.
- 828 17 Singh RB, Blanco T, Mittal SK, Taketani Y, Chauhan SK, Chen Y, *et al.* Pigment  
829 Epithelium-derived Factor secreted by corneal epithelial cells regulates dendritic cell  
830 maturation in dry eye disease. *Ocular Surface* 2020;**18**:460–9.  
831 <https://doi.org/10.1016/j.jtos.2020.05.002>.
- 832 18 Tombran-Tink J, Johnson L V. Neuronal differentiation of retinoblastoma cells induced by  
833 medium conditioned by human RPE cells. *Invest Ophthalmol Vis Sci* 1989;**30**:1700–7.
- 834 19 Alberdi E, Aymerich MS, Becerra SP. Binding of Pigment Epithelium-derived Factor  
835 (PEDF) to Retinoblastoma Cells and Cerebellar Granule Neurons: EVIDENCE FOR A  
836 PEDF RECEPTOR \*. *Journal of Biological Chemistry* 1999;**274**:31605–12.  
837 <https://doi.org/10.1074/JBC.274.44.31605>.
- 838 20 Chen X, Xu M, Zhang X, Barnstable CJ, Li X, Tombran-Tink J. Deletion of the *Pedf* gene  
839 leads to inflammation, photoreceptor loss and vascular disturbances in the retina. *Exp Eye*  
840 *Res* 2022;**222**:109171. <https://doi.org/10.1016/J.EXER.2022.109171>.
- 841 21 Zamiri P, Masli S, Streilein JW, Taylor AW. Pigment Epithelial Growth Factor Suppresses  
842 Inflammation by Modulating Macrophage Activation. *Invest Ophthalmol Vis Sci*  
843 2006;**47**:3912–8. <https://doi.org/10.1167/IOVS.05-1267>.
- 844 22 Park K, Jin J, Hu Y, Zhou K, Ma J-X. Overexpression of Pigment Epithelium-Derived  
845 Factor Inhibits Retinal Inflammation and Neovascularization. *Am J Pathol* 2011;**178**:688–  
846 98. <https://doi.org/10.1016/j.ajpath.2010.10.014>.
- 847 23 Polato F, Becerra SP. Pigment Epithelium-Derived Factor, a Protective Factor for  
848 Photoreceptors in Vivo. *Adv Exp Med Biol* 2016;**854**:699. [https://doi.org/10.1007/978-3-319-17121-0\\_93](https://doi.org/10.1007/978-3-319-17121-0_93).
- 850 24 Cayouette M, Smith SB, Becerra SP, Gravel C. Pigment Epithelium-Derived Factor  
851 Delays the Death of Photoreceptors in Mouse Models of Inherited Retinal Degenerations.  
852 *Neurobiol Dis* 1999;**6**:523–32. <https://doi.org/10.1006/NBDI.1999.0263>.
- 853 25 Taniwaki T, Hirashima N, Becerra SP, Chader GJ, Etcheberrigaray R, Schwartz JP.  
854 Pigment Epithelium-Derived Factor Protects Cultured Cerebellar Granule Cells Against  
855 Glutamate-Induced Neurotoxicity. *J Neurochem* 1997;**68**:26–32.  
856 <https://doi.org/10.1046/J.1471-4159.1997.68010026.X>.
- 857 26 Bilak MM, Corse AM, Bilak SR, Lehar M, Tombran-Tink J, Kuncl RW. Pigment  
858 Epithelium-derived Factor (PEDF) Protects Motor Neurons from Chronic Glutamate-  
859 mediated Neurodegeneration. *J Neuropathol Exp Neurol* 1999;**58**:719–28.  
860 <https://doi.org/10.1097/00005072-199907000-00006>.

- 861 27 Taniwaki T, Becerra SP, Chader GJ, Schwartz JP. Pigment epithelium-derived factor is a  
862 survival factor for cerebellar granule cells in culture. *J Neurochem* 1995;**64**:2509–17.  
863 <https://doi.org/10.1046/J.1471-4159.1995.64062509.X>.
- 864 28 An E, Lu X, Flippin J, Devaney JM, Halligan B, Hoffman E, *et al*. Secreted proteome  
865 profiling in human RPE cell cultures derived from donors with age related macular  
866 degeneration and age matched healthy donors. *J Proteome Res* 2006;**5**:2599–610.  
867 <https://doi.org/10.1021/pr060121j>.
- 868 29 Yuan X, Gu X, Crabb JS, Yue X, Shadrach K, Hollyfield JG, *et al*. Quantitative  
869 proteomics: Comparison of the macular bruch membrane/choroid complex from age-  
870 related macular degeneration and normal eyes. *Molecular and Cellular Proteomics*  
871 2010;**9**:1031–46. <https://doi.org/10.1074/mcp.M900523-MCP200>.
- 872 30 Priglinger CS, Obermann J, Szober CM, Merl-Pham J, Ohmayer U, Behler J, *et al*.  
873 Epithelial-to-mesenchymal transition of RPE cells in vitro confers increased  $\beta$ 1,6-N-  
874 Glycosylation and Increased Susceptibility to Galectin-3 Binding. *PLoS One*  
875 2016;**11**:e0146887. <https://doi.org/10.1371/journal.pone.0146887>.
- 876 31 Hughes RC. Secretion of the galectin family of mammalian carbohydrate-binding  
877 proteins. *Biochim Biophys Acta Gen Subj* 1999:172–85. [https://doi.org/10.1016/S0304-4165\(99\)00177-4](https://doi.org/10.1016/S0304-4165(99)00177-4).
- 879 32 Caridi B, Doncheva D, Sivaprasad S, Turowski P. Galectins in the Pathogenesis of  
880 Common Retinal Disease. *Front Pharmacol* 2021;**12**:.  
881 <https://doi.org/10.3389/fphar.2021.687495>.
- 882 33 García-Revilla J, Boza-Serrano A, Espinosa-Oliva AM, Soto MS, Deierborg T, Ruiz R, *et al*.  
883 Galectin-3, a rising star in modulating microglia activation under conditions of  
884 neurodegeneration. *Cell Death & Disease* 2022 *13*:7 2022;**13**:1–11.  
885 <https://doi.org/10.1038/s41419-022-05058-3>.
- 886 34 Henderson NC, Sethi T. The regulation of inflammation by galectin-3. *Immunol Rev*  
887 2009;**230**:160–71. <https://doi.org/10.1111/J.1600-065X.2009.00794.X>.
- 888 35 Priglinger CS, Obermann J, Szober CM, Merl-Pham J, Ohmayer U, Behler J, *et al*.  
889 Epithelial-to-Mesenchymal Transition of RPE Cells In Vitro Confers Increased  $\beta$ 1,6-N-  
890 Glycosylation and Increased Susceptibility to Galectin-3 Binding. *PLoS One* 2016;**11**:.  
891 <https://doi.org/10.1371/JOURNAL.PONE.0146887>.
- 892 36 Li Z-Y, M Tso MO, Wongf H, Organisciakf DT. Amelioration of photic injury in rat retina  
893 by ascorbic acid: a histopathologic study. *Invest Ophthalmol Vis Sci* 1985;**26**:1589–98.
- 894 37 Organisciak DT, Wong H-M, Li Z-Y, Tsof MOM. The protective effect of ascorbate in  
895 retinal light damage of rats. *Invest Ophthalmol Vis Sci* 1985;**26**:1580–8.
- 896 38 Zhang N, Zhang X, Girardot PE, Chrenek MA, Sellers JT, Li Y, *et al*. Electrophysiologic  
897 and Morphologic Strain Differences in a Low-Dose NaIO<sub>3</sub>-Induced Retinal Pigment  
898 Epithelium Damage Model. *Transl Vis Sci Technol* 2021;**10**:.  
899 <https://doi.org/10.1167/TVST.10.8.10>.
- 900 39 Boatright JH, Dalal N, Chrenek MA, Gardner C, Ziesel A, Jiang Y, *et al*. Methodologies  
901 for analysis of patterning in the mouse RPE sheet. *Mol Vis* 2015;**21**:40.
- 902 40 Zhang Q, Chrenek MA, Bhatia S, Rashid A, Ferdous S, Donaldson KJ, *et al*. Comparison  
903 of histologic findings in age-related macular degeneration with RPE flatmount images.  
904 *Mol Vis* 2019;**25**:70–8.

- 905 41 Sun N, Shibata B, Hess JF, Fitzgerald PG. An alternative means of retaining ocular  
906 structure and improving immunoreactivity for light microscopy studies. *Mol Vis*  
907 2015;**21**:428.
- 908 42 Sun N, Shibata B, Hess JF, Fitzgerald PG. An alternative means of retaining ocular  
909 structure and improving immunoreactivity for light microscopy studies. *Mol Vis*  
910 2015;**21**:428.
- 911 43 Ferdous S, Shelton DA, Getz TE, Chrenek MA, L'Hernault N, Sellers JT, *et al.* Deletion  
912 of histone demethylase Lsd1 (Kdm1a) during retinal development leads to defects in  
913 retinal function and structure. *Front Cell Neurosci* 2023;**17**:1104592.  
914 <https://doi.org/10.3389/FNCEL.2023.1104592/FULL>.
- 915 44 Huber G, Beck SC, Grimm C, Sahaboglu-Tekgoz A, Paquet-Durand F, Wenzel A, *et al.*  
916 Spectral Domain Optical Coherence Tomography in Mouse Models of Retinal  
917 Degeneration. *Invest Ophthalmol Vis Sci* 2009;**50**:5888–95.  
918 <https://doi.org/10.1167/IOVS.09-3724>.
- 919 45 Bilak MM, Patricia Becerra S, Vincent AM, Moss BH, Aymerich MS, Kuncl RW.  
920 Identification of the Neuroprotective Molecular Region of Pigment Epithelium-Derived  
921 Factor and Its Binding Sites on Motor Neurons. *Journal of Neuroscience* 2002;**22**:9378–  
922 86. <https://doi.org/10.1523/JNEUROSCI.22-21-09378.2002>.
- 923 46 Murakami Y, Ikeda Y, Yonemitsu Y, Onimaru M, Nakagawa K, Kohno RI, *et al.* Inhibition  
924 of Nuclear Translocation of Apoptosis-Inducing Factor Is an Essential Mechanism of the  
925 Neuroprotective Activity of Pigment Epithelium-Derived Factor in a Rat Model of Retinal  
926 Degeneration. *Am J Pathol* 2008;**173**:1326. <https://doi.org/10.2353/AJPATH.2008.080466>.
- 927 47 Cao W, Tombran-Tink J, Elias R, Sezate S, McGinnis JF. Role of Pigment Epithelium-  
928 Derived Factor (PEDF) in Photoreceptor Cell Protection. *New Insights Into Retinal*  
929 *Degenerative Diseases* 2001:119–26. [https://doi.org/10.1007/978-1-4615-1355-1\\_14](https://doi.org/10.1007/978-1-4615-1355-1_14).
- 930 48 Rapp L, Williams T. A parametric study of retinal light damage in albino and pigmented  
931 rats. *The Effects of Constant Light on Visual Processes Plenum Press, New York*  
932 1980:133–59.
- 933 49 Organisciak DT, Vaughan DK. Retinal light damage: Mechanisms and protection. *Prog*  
934 *Retin Eye Res* 2010:113–34. <https://doi.org/10.1016/j.preteyeres.2009.11.004>.
- 935 50 Gordan WC, Casey DM, Lukiw WJ, Bazan NG. DNA Damage and Repair in Light-  
936 Induced Photoreceptor Degeneration. *Invest Ophthalmol Vis Sci* 2002:3511–21.
- 937 51 Chen Y, Yang J, Geng H, Li L, Li J, Cheng B, *et al.* Photoreceptor degeneration in  
938 microphthalmia (Mitf) mice: partial rescue by pigment epithelium-derived factor. *Dis*  
939 *Model Mech* 2019;**12**:. <https://doi.org/10.1242/DMM.035642>.
- 940 52 Sivakumar V, Zhang Y, Ling EA, Foulds WS, Kaur C. Insulin-like growth factors,  
941 angiopoietin-2, and pigment epithelium-derived growth factor in the hypoxic retina. *J*  
942 *Neurosci Res* 2008;**86**:702–11. <https://doi.org/10.1002/JNR.21519>.
- 943 53 Liao R, Yan F, Zeng Z, Wang H, Qiu K, Xu J, *et al.* Insulin-like growth factor-1 activates  
944 PI3K/Akt signalling to protect human retinal pigment epithelial cells from amiodarone-  
945 induced oxidative injury. *Br J Pharmacol* 2018;**175**:125.  
946 <https://doi.org/10.1111/BPH.14078>.
- 947 54 Haurigot V, Villacampa P, Ribera A, Bosch A, Ramos D, Ruberte J, *et al.* Long-Term  
948 Retinal PEDF Overexpression Prevents Neovascularization in a Murine Adult Model of  
949 Retinopathy. *PLoS One* 2012;**7**:e41511.  
950 <https://doi.org/10.1371/JOURNAL.PONE.0041511>.

- 951 55 Arroba AI, Campos-Caro A, Aguilar-Diosdado M, Valverde ÁM. IGF-1, Inflammation and  
952 Retinal Degeneration: A Close Network. *Front Aging Neurosci* 2018;**10**:203.  
953 <https://doi.org/10.3389/FNAGI.2018.00203>.
- 954 56 Arroba AI, Álvarez-Lindo N, van Rooijen N, de la Rosa EJ. Microglia-mediated IGF-I  
955 neuroprotection in the rd10 mouse model of retinitis pigmentosa. *Invest Ophthalmol Vis  
956 Sci* 2011;**52**:9124–30. <https://doi.org/10.1167/IOVS.11-7736>.
- 957 57 Singh RB, Blanco T, Mittal SK, Alemi H, Chauhan SK, Chen Y, *et al*. Pigment  
958 Epithelium–Derived Factor Enhances the Suppressive Phenotype of Regulatory T Cells in  
959 a Murine Model of Dry Eye Disease. *American Journal of Pathology* 2021;**191**:720–9.  
960 <https://doi.org/10.1016/j.ajpath.2021.01.003>.
- 961 58 Yamawaki T, Ito E, Mukai A, Ueno M, Yamada J, Sotozono C, *et al*. The ingenious  
962 interactions between macrophages and functionally plastic retinal pigment epithelium  
963 cells. *Invest Ophthalmol Vis Sci* 2016;**57**:5945–53. <https://doi.org/10.1167/iov.16-20604>.
- 964 59 Ueno S, Sudo T, Saya H, Sugihara E. Pigment epithelium-derived factor promotes  
965 peritoneal dissemination of ovarian cancer through induction of immunosuppressive  
966 macrophages. *Communications Biology* 2022 5:1 2022;**5**:1–16.  
967 <https://doi.org/10.1038/s42003-022-03837-4>.
- 968 60 Takanohashi A, Yabe T, Schwartz JP. Pigment epithelium-derived factor induces the  
969 production of chemokines by rat microglia. *Glia* 2005;**51**:266–78.  
970 <https://doi.org/10.1002/glia.20203>.
- 971 61 Yamagishi S, Koga Y, Sotokawauchi A, Hashizume N, Fukahori S, Matsui T, *et al*.  
972 Therapeutic Potential of Pigment Epithelium-derived Factor in Cancer. *Curr Pharm Des*  
973 2019;**25**:313–24. <https://doi.org/10.2174/1381612825666190319112106>.
- 974 62 Bernardo-Colón A, Lerner M, Becerra SP. Pigment epithelium-derived factor is an  
975 interleukin-6 antagonist in the RPE: Insight of structure-function relationships. *Front  
976 Physiol* 2022;**13**:. <https://doi.org/10.3389/FPHYS.2022.1045613>.
- 977 63 O’Koren EG, Yu C, Klingeborn M, Wong AYW, Prigge CL, Mathew R, *et al*. Microglial  
978 Function Is Distinct in Different Anatomical Locations during Retinal Homeostasis and  
979 Degeneration. *Immunity* 2019;**50**:723-737.e7.  
980 <https://doi.org/10.1016/j.immuni.2019.02.007>.
- 981 64 Yu C, Lad EM, Mathew R, Littleton S, Chen Y, Schlepckow K, *et al*. Microglia at Sites of  
982 Atrophy Restrict the Progression of Retinal Degeneration via Galectin-3 and Trem2  
983 Interactions. *BioRxiv* 2023. <https://doi.org/10.1101/2023.07.19.549403>.
- 984 65 Pitts KM, Neeson CE, Hall NE, Lin JB, Falah HK, Wang SL, *et al*. Neurodegeneration  
985 Markers Galectin-3 and Apolipoprotein E Are Elevated in the Aqueous Humor of Eyes  
986 With Glaucoma. *Transl Vis Sci Technol* 2022;**11**:. <https://doi.org/10.1167/TVST.11.11.1>.
- 987 66 Bauer PM, Zalis MC, Abdshill H, Deierborg T, Johansson F, Englund-Johansson U.  
988 Inflamed In Vitro Retina: Cytotoxic Neuroinflammation and Galectin-3 Expression. *PLoS  
989 One* 2016;**11**:. <https://doi.org/10.1371/JOURNAL.PONE.0161723>.
- 990 67 Hata-Mizuno M, Uchino Y, Uchino M, Shimmura S, Ogawa Y, Tsubota K, *et al*. Analysis  
991 of the Association between Galectin-3 Concentration in Tears and the Severity of Dry Eye  
992 Disease: A Case-Control Study. *Journal of Clinical Medicine* 2022, Vol 11, Page 66  
993 2021;**11**:66. <https://doi.org/10.3390/JCM11010066>.
- 994 68 Kumar S, Ranawat CS, Bhandiwad C, Arya H, Mali M, Singh CP, *et al*. Galectin-3 as a  
995 Potential Biomarker of Microvascular Complications in Patients with Type 2 Diabetes.  
996 *Indian J Endocrinol Metab* 2022;**26**:490. [https://doi.org/10.4103/IJEM.IJEM\\_270\\_22](https://doi.org/10.4103/IJEM.IJEM_270_22).



- 997 69 Zhou ZY, Chang TF, Lin Z Bin, Jing YT, Wen LS, Niu YL, *et al.* Microglial Galectin3  
998 enhances endothelial metabolism and promotes pathological angiogenesis via Notch  
999 inhibition by competitively binding to Jag1. *Cell Death & Disease* 2023 14:6 2023;14:1–  
1000 15. <https://doi.org/10.1038/s41419-023-05897-8>.
- 1001 70 Liu Y, Zhao C, Meng J, Li N, Xu Z, Liu X, *et al.* Galectin-3 regulates microglial activation  
1002 and promotes inflammation through TLR4/MyD88/NF- $\kappa$ B in experimental autoimmune  
1003 uveitis. *Clinical Immunology* 2022;236:108939.  
1004 <https://doi.org/10.1016/J.CLIM.2022.108939>.
- 1005 71 Tabel M, Wolf A, Szczepan M, Xu H, Jäggle H, Moehle C, *et al.* Genetic targeting or  
1006 pharmacological inhibition of galectin-3 dampens microglia reactivity and delays retinal  
1007 degeneration. *J Neuroinflammation* 2022;19:229. [https://doi.org/10.1186/S12974-022-](https://doi.org/10.1186/S12974-022-02589-6)  
1008 [02589-6](https://doi.org/10.1186/S12974-022-02589-6).
- 1009 72 Cao W, Tombran-Tink J, Elias R, Sezate S, Mrazek D, McGinnis JF. In vivo protection of  
1010 photoreceptors from light damage by pigment epithelium-derived factor. *Invest*  
1011 *Ophthalmol Vis Sci* 2001;42:1646–52.
- 1012 73 Ortín-Martínez A, Valiente-Soriano FJ, García-Ayuso D, Alarcón-Martínez L, Jiménez-  
1013 López M, Bernal-Garro JM, *et al.* A Novel In Vivo Model of Focal Light Emitting Diode-  
1014 Induced Cone-Photoreceptor Phototoxicity: Neuroprotection Afforded by Brimonidine,  
1015 BDNF, PEDF or bFGF. *PLoS One* 2014;9:.  
1016 <https://doi.org/10.1371/JOURNAL.PONE.0113798>.
- 1017 74 MEDAWAR PB. Immunity to Homologous Grafted Skin. III. The Fate of Skin  
1018 Homographs Transplanted to the Brain, to Subcutaneous Tissue, and to the Anterior  
1019 Chamber of the Eye. *Br J Exp Pathol* 1948;29:58.
- 1020 75 Streilein JW, Ma N, Wenkel H, Fong Ng T, Zamiri P. Immunobiology and privilege of  
1021 neuronal retina and pigment epithelium transplants. *Vision Res* 2002;42:487–95.  
1022 [https://doi.org/10.1016/S0042-6989\(01\)00185-7](https://doi.org/10.1016/S0042-6989(01)00185-7).
- 1023 76 Wayne J, Boston S. Immunological non-responsiveness and acquisition of tolerance in  
1024 relation to immune privilege in the eye. *Eye* 1995 9:2 1995;9:236–40.  
1025 <https://doi.org/10.1038/eye.1995.46>.
- 1026 77 Qiao H, Lucas K, Stein-Streilein J. Retinal Laser Burn Disrupts Immune Privilege in the  
1027 Eye. *Am J Pathol* 2009;174:414. <https://doi.org/10.2353/AJPATH.2009.080766>.
- 1028 78 Lucas K, Karamichos D, Mathew R, Zieske JD, Stein-Streilein J. Retinal laser burn (RLB)  
1029 induced neuropathy leads to substance P dependent loss of ocular immune privilege. *J*  
1030 *Immunol* 2012;189:1237. <https://doi.org/10.4049/JIMMUNOL.1103264>.
- 1031 79 Taylor AW, Hsu S, Ng TF. The Role of Retinal Pigment Epithelial Cells in Regulation of  
1032 Macrophages/Microglial Cells in Retinal Immunobiology. *Front Immunol* 2021;12:3256.  
1033 <https://doi.org/10.3389/FIMMU.2021.724601/BIBTEX>.
- 1034 80 Taylor AW, Wayne Streilein J, Cousins SW. Alpha-melanocyte-stimulating hormone  
1035 suppresses antigen-stimulated T cell production of gamma-interferon.  
1036 *Neuroimmunomodulation* 1994;1:188–94. <https://doi.org/10.1159/000097167>.
- 1037 81 Benque IJ, Xia P, Shannon R, Ng TF, Taylor AW. The Neuropeptides of Ocular Immune  
1038 Privilege,  $\alpha$ -MSH and NPY, Suppress Phagosome Maturation in Macrophages.  
1039 *Immunohorizons* 2018;2:314–23. <https://doi.org/10.4049/IMMUNOHORIZONS.1800049>.
- 1040 82 Kawanaka N, Taylor AW. Localized retinal neuropeptide regulation of macrophage and  
1041 microglial cell functionality. *J Neuroimmunol* 2011;232:17.  
1042 <https://doi.org/10.1016/J.JNEUROIM.2010.09.025>.

- 1043 83 Phan TA, Taylor AW. The neuropeptides  $\alpha$ -MSH and NPY modulate phagocytosis and  
1044 phagolysosome activation in RAW 264.7 cells. *J Neuroimmunol* 2013;**260**:9–16.  
1045 <https://doi.org/10.1016/J.JNEUROIM.2013.04.019>.
- 1046 84 Ma JYW, Greferath U, Wong JHC, Fothergill LJ, Jobling AI, Vessey KA, *et al.* Aging  
1047 induces cell loss and a decline in phagosome processing in the mouse retinal pigment  
1048 epithelium. *Neurobiol Aging* 2023;**128**:1–16.  
1049 <https://doi.org/10.1016/J.NEUROBIOLAGING.2023.03.003>.
- 1050 85 Zhang SX, Wang JJ, Gao G, Shao C, Mott R, Ma J. Pigment epithelium-derived factor  
1051 (PEDF) is an endogenous antiinflammatory factor. *The FASEB Journal* 2006;**20**:323–5.  
1052 <https://doi.org/10.1096/FJ.05-4313FJE>.
- 1053 86 Kenealey J, Subramanian P, Comitato A, Bullock J, Keehan L, Polato F, *et al.* Small  
1054 Retinoprotective Peptides Reveal a Receptor-binding Region on Pigment Epithelium-  
1055 derived Factor \*. *Journal of Biological Chemistry* 2015;**290**:25241–53.  
1056 <https://doi.org/10.1074/JBC.M115.645846>.
- 1057 87 Sanchez A, Tripathy D, Yin X, Luo J, Martinez J, Grammas P. Pigment epithelium-derived  
1058 factor (PEDF) protects cortical neurons in vitro from oxidant injury by activation of  
1059 extracellular signal-regulated kinase (ERK) 1/2 and induction of Bcl-2. *Neurosci Res*  
1060 2012;**72**:1. <https://doi.org/10.1016/J.NEURES.2011.09.003>.
- 1061 88 He T, Liu W, Shen CAA. Anti-inflammatory properties of pigment epithelium-derived  
1062 factor. <https://doi.org/10.1177/1721727X221138857> 2022;**20**:.  
1063 <https://doi.org/10.1177/1721727X221138857>.
- 1064 89 Rebutini IT, Crawford SE, Becerra SP. PEDF Deletion Induces Senescence and Defects  
1065 in Phagocytosis in the RPE. *International Journal of Molecular Sciences* 2022, Vol 23,  
1066 Page 7745 2022;**23**:7745. <https://doi.org/10.3390/IJMS23147745>.
- 1067 90 Rajala A, Teel K, Bhat MA, Batushansky A, Griffin TM, Purcell L, *et al.* Insulin-like  
1068 growth factor 1 receptor mediates photoreceptor neuroprotection. *Cell Death Dis*  
1069 2022;**13**:. <https://doi.org/10.1038/S41419-022-05074-3>.
- 1070 91 Jones AL, Dhanapala L, Baldo TA, Sharafeldin M, Krause CE, Shen M, *et al.* Prostate  
1071 Cancer Diagnosis in the Clinic Using an 8-Protein Biomarker Panel. *Anal Chem*  
1072 2021;**93**:1059–67.  
1073 <https://doi.org/10.1021/ACS.ANALCHEM.0C04034/ASSET/IMAGES/LARGE/AC0C04>  
1074 [034\\_0006.JPEG](https://doi.org/10.1021/ACS.ANALCHEM.0C04034/ASSET/IMAGES/LARGE/AC0C04034_0006.JPEG).
- 1075 92 O'Donnell SL, Frederick TJ, Krady JK, Vannucci SJ, Wood TL. IGF-I and  
1076 microglia/macrophage proliferation in the ischemic mouse brain. *Glia* 2002;**39**:85–97.  
1077 <https://doi.org/10.1002/glia.10081>.
- 1078 93 Bellver-Landete V, Bretheau F, Mailhot B, Vallières N, Lessard M, Janelle M-E, *et al.*  
1079 Microglia are an essential component of the neuroprotective scar that forms after spinal  
1080 cord injury n.d. <https://doi.org/10.1038/s41467-019-08446-0>.
- 1081 94 Rodriguez-de la Rosa L, Fernandez-Sanchez L, Germain F, Murillo-Cuesta S, Varela-  
1082 Nieto I, de la Villa P, *et al.* Age-related functional and structural retinal modifications in  
1083 the Igf1<sup>-/-</sup> null mouse. *Neurobiol Dis* 2012;**46**:476–85.  
1084 <https://doi.org/10.1016/J.NBD.2012.02.013>.
- 1085 95 Kermer P, Klöcker N, Labes M, Bähr M. Insulin-Like Growth Factor-I Protects  
1086 Axotomized Rat Retinal Ganglion Cells from Secondary Death via PI3-K-Dependent Akt  
1087 Phosphorylation and Inhibition of Caspase-3 In Vivo. *Journal of Neuroscience*  
1088 2000;**20**:722–8. <https://doi.org/10.1523/JNEUROSCI.20-02-00722.2000>.

- 1089 96 Politi LE, Rotstein NP, Salvador G, Giusto NM, Fernanda Insua M. Insulin-like growth  
1090 factor-I is a potential trophic factor for amacrine cells. *J Neurochem* 2001;**76**:1199–211.  
1091 <https://doi.org/10.1046/J.1471-4159.2001.00128.X>.
- 1092 97 Lalancette-Hébert M, Swarup V, Beaulieu JM, Bohacek I, Abdelhamid E, Weng YC, *et al.*  
1093 Galectin-3 is required for resident microglia activation and proliferation in response to  
1094 ischemic injury. *Journal of Neuroscience* 2012;**32**:10383–95.  
1095 <https://doi.org/10.1523/JNEUROSCI.1498-12.2012>.
- 1096 98 Spadaro O, Camell CD, Bosurgi L, Nguyen KY, Youm YH, Rothlin C V., *et al.* IGF1  
1097 shapes the macrophage activation in response to immunometabolic challenge. *Cell Rep*  
1098 2017;**19**:225. <https://doi.org/10.1016/J.CELREP.2017.03.046>.
- 1099 99 Lee DC, Ruiz CR, Lebson L, Selenica MLB, Rizer J, Hunt JB, *et al.* Aging enhances  
1100 classical activation but mitigates alternative activation in the CNS. *Neurobiol Aging*  
1101 2013;**34**:1610. <https://doi.org/10.1016/J.NEUROBIOLAGING.2012.12.014>.
- 1102 100 Santos CL, Bobermin LD, Quincozes-Santos A. Aging changes the expression of  
1103 adenosine receptors, insulin-like growth factor 1 (IGF1), and hypoxia-inducible factor 1 $\alpha$   
1104 (HIF1 $\alpha$ ) in hypothalamic astrocyte cultures. *Aging Brain* 2024;**5**:100104.  
1105 <https://doi.org/10.1016/J.NBAS.2023.100104>.
- 1106 101 Toth L, Czigler A, Hegedus E, Komaromy H, Amrein K, Czeiter E, *et al.* Age-related  
1107 decline in circulating IGF-1 associates with impaired neurovascular coupling responses in  
1108 older adults. *Geroscience* 2022;**44**:2771–83. [https://doi.org/10.1007/S11357-022-00623-](https://doi.org/10.1007/S11357-022-00623-2/FIGURES/5)  
1109 [2/FIGURES/5](https://doi.org/10.1007/S11357-022-00623-2/FIGURES/5).
- 1110 102 Holtman IR, Raj DD, Miller JA, Schaafsma W, Yin Z, Brouwer N, *et al.* Induction of a  
1111 common microglia gene expression signature by aging and neurodegenerative conditions:  
1112 a co-expression meta-analysis. *Acta Neuropathol Commun* 2015;**3**:31.  
1113 <https://doi.org/10.1186/s40478-015-0203-5>.
- 1114 103 Siew JJ, Chen HM, Chen HY, Chen HL, Chen CM, Soong BW, *et al.* Galectin-3 is  
1115 required for the microglia-mediated brain inflammation in a model of Huntington's  
1116 disease. *Nature Communications* 2019 10:1 2019;**10**:1–18.  
1117 <https://doi.org/10.1038/s41467-019-11441-0>.
- 1118 104 Rahimian R, Lively S, Abdelhamid E, Lalancette-Hébert M, Schlichter L, Sato S, *et al.*  
1119 Delayed Galectin-3-Mediated Reprogramming of Microglia After Stroke is Protective  
1120 2018. <https://doi.org/10.1007/s12035-019-1527-0>.
- 1121 105 O'Koren EG, Yu C, Klingeborn M, Wong AYW, Prigge CL, Mathew R, *et al.* Microglial  
1122 Function Is Distinct in Different Anatomical Locations during Retinal Homeostasis and  
1123 Degeneration. *Immunity* 2019;**50**:723-737.e7.  
1124 <https://doi.org/10.1016/j.immuni.2019.02.007>.
- 1125 106 Yu C, Saban DR. Identification of a Unique Subretinal Microglia Type in Retinal  
1126 Degeneration Using Single Cell RNA-Seq. *Adv Exp Med Biol*, vol. 1185. Springer; 2019.  
1127 p. 181–6.
- 1128 107 An E, Lu X, Flippin J, Devaney JM, Halligan B, Hoffman E, *et al.* Secreted proteome  
1129 profiling in human RPE cell cultures derived from donors with age related macular  
1130 degeneration and age matched healthy donors. *J Proteome Res* 2006;**5**:2599–610.  
1131 <https://doi.org/10.1021/PR060121J/ASSET/IMAGES/MEDIUM/PR060121JN00001.GIF>.
- 1132 108 Ardeljan D, Chan CC. Aging is not a disease: distinguishing age-related macular  
1133 degeneration from aging. *Prog Retin Eye Res* 2013;**37**:68–89.  
1134 <https://doi.org/10.1016/J.PRETEYERES.2013.07.003>.

- 1135 109 Fernandez CG, Hamby ME, McReynolds ML, Ray WJ. The role of apoE4 in disrupting  
1136 the homeostatic functions of astrocytes and microglia in aging and Alzheimer’s disease.  
1137 *Front Aging Neurosci* 2019;**10**:14. <https://doi.org/10.3389/fnagi.2019.00014>.
- 1138 110 Ma W, Cojocaru R, Gotoh N, Gieser L, Villasmil R, Cogliati T, *et al.* Gene expression  
1139 changes in aging retinal microglia: Relationship to microglial support functions and  
1140 regulation of activation. *Neurobiol Aging* 2013;**34**:2310–21.  
1141 <https://doi.org/10.1016/j.neurobiolaging.2013.03.022>.
- 1142 111 Chen M, Muckersie E, Forrester J V., Xu H. Immune Activation in Retinal Aging: A Gene  
1143 Expression Study. *Invest Ophthalmol Vis Sci* 2010;**51**:5888–96.  
1144 <https://doi.org/10.1167/IOVS.09-5103>.
- 1145 112 Xu H, Chen M, Forrester J V. Para-inflammation in the aging retina. *Prog Retin Eye Res*  
1146 2009;**28**:348–68. <https://doi.org/10.1016/J.PRETEYERES.2009.06.001>.
- 1147 113 Miller EB, Zhang P, Ching K, Pugh EN, Burns ME. In vivo imaging reveals transient  
1148 microglia recruitment and functional recovery of photoreceptor signaling after injury. *Proc*  
1149 *Natl Acad Sci U S A* 2019;**116**:16603–12. <https://doi.org/10.1073/pnas.1903336116>.
- 1150 114 Karlen SJ, Miller EB, Wang X, Levine ES, Zawadzki RJ, Burns ME. Monocyte  
1151 infiltration rather than microglia proliferation dominates the early immune response to  
1152 rapid photoreceptor degeneration. *J Neuroinflammation* 2018;**15**:344.  
1153 <https://doi.org/10.1186/s12974-018-1365-4>.
- 1154 115 Ma B, Zhou Y, Liu R, Zhang K, Yang T, Hu C, *et al.* Pigment epithelium-derived factor  
1155 (PEDF) plays anti-inflammatory roles in the pathogenesis of dry eye disease. *Ocul Surf*  
1156 2021;**20**:70–85. <https://doi.org/10.1016/J.JTOS.2020.12.007>.
- 1157  
1158  
1159  
1160  
1161  
1162  
1163  
1164  
1165  
1166  
1167  
1168